ID HLAB_HUMAN Reviewed; 362 AA.
AC P01889; A0A2I6Q7B5; B0V0B8; G3GN01; O02862; O02956; O02957; O02960; O19555;
AC O19556; O19595; O19615; O19624; O19625; O19627; O19641; O19651; O19675;
AC O19692; O19758; O19779; O19783; O46702; O62897; O62901; O62915; O62917;
AC O62919; O77933; O77959; O78053; O78138; O78160; O78163; O78172; O78173;
AC O78180; O78217; O95730; O98140; P01890; P03989; P10317; P10318; P10319;
AC P10320; P18463; P18464; P18465; P19373; P30460; P30461; P30462; P30463;
AC P30464; P30465; P30466; P30467; P30468; P30469; P30470; P30471; P30472;
AC P30473; P30474; P30475; P30476; P30477; P30478; P30479; P30480; P30481;
AC P30482; P30483; P30484; P30485; P30486; P30487; P30488; P30489; P30490;
AC P30491; P30492; P30493; P30494; P30495; P30496; P30497; P30498; P30513;
AC P30685; P79489; P79490; P79496; P79504; P79523; P79524; P79542; P79555;
AC Q04826; Q08136; Q29633; Q29636; Q29638; Q29661; Q29665; Q29678; Q29679;
AC Q29681; Q29693; Q29695; Q29697; Q29718; Q29742; Q29749; Q29762; Q29764;
AC Q29829; Q29836; Q29842; Q29845; Q29846; Q29847; Q29848; Q29850; Q29851;
AC Q29852; Q29854; Q29855; Q29857; Q29858; Q29861; Q29924; Q29925; Q29933;
AC Q29935; Q29936; Q29940; Q29953; Q29961; Q29982; Q30173; Q30198; Q31603;
AC Q31610; Q31612; Q31613; Q546L8; Q546M4; Q5JP37; Q5QT24; Q5RIP1; Q5SRJ2;
AC Q5TK76; Q5TK77; Q860I4; Q861B5; Q8HWF0; Q8MGQ3; Q8MHN4; Q8SNC5; Q95343;
AC Q95344; Q95365; Q95369; Q95392; Q95HA3; Q95HA8; Q95HM9; Q95IA6; Q95IB8;
AC Q95IH5; Q95J00; Q96IT9; Q9BCM6; Q9BCM7; Q9BCM8; Q9BD06; Q9BD38; Q9BD43;
AC Q9GIL3; Q9GIM3; Q9GIX1; Q9GIY5; Q9GIZ0; Q9GIZ9; Q9GJ00; Q9GJ17; Q9GJ20;
AC Q9GJ23; Q9GJ31; Q9GJF0; Q9GJM7; Q9MX21; Q9MY37; Q9MY42; Q9MY43; Q9MY61;
AC Q9MY75; Q9MY78; Q9MY79; Q9MY84; Q9MY92; Q9MY93; Q9MY94; Q9MYB8; Q9MYC3;
AC Q9MYC7; Q9MYF4; Q9MYG1; Q9TP35; Q9TP36; Q9TP37; Q9TP95; Q9TPQ7; Q9TPQ9;
AC Q9TPR2; Q9TPR4; Q9TPS6; Q9TPT2; Q9TPT4; Q9TPT6; Q9TPV2; Q9TQG1; Q9TQH3;
AC Q9TQH6; Q9TQH7; Q9TQH8; Q9TQH9; Q9TQM2; Q9TQN4; Q9TQN6; Q9UQS8; Q9UQT0;
DT 21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT 01-FEB-1991, sequence version 3.
DT 27-MAR-2024, entry version 224.
DE RecName: Full=HLA class I histocompatibility antigen, B alpha chain;
DE AltName: Full=Human leukocyte antigen B;
DE Short=HLA-B;
DE Flags: Precursor;
GN Name=HLA-B {ECO:0000312|HGNC:HGNC:4932}; Synonyms=HLAB;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*40:01).
RX PubMed=2437025; DOI=10.1007/bf00404425;
RA Ways J.W., Lawlor D.A., Wan A.M., Parham P.;
RT "A transposable epitope of HLA-B7, B40 molecules.";
RL Immunogenetics 25:323-328(1987).
RN [2]
RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELES B*07:02; B*37:01; B*51:01 AND B*57:01).
RX PubMed=2320591; DOI=10.1073/pnas.87.7.2833;
RA Ennis P.D., Zemmour J., Salter R.D., Parham P.;
RT "Rapid cloning of HLA-A,B cDNA by using the polymerase chain reaction:
RT frequency and nature of errors produced in amplification.";
RL Proc. Natl. Acad. Sci. U.S.A. 87:2833-2837(1990).
RN [3]
RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*54:01; B*55:01 AND B*56:01).
RX PubMed=1737933;
RA Hildebrand W.H., Madrigal J.A., Little A.-M., Parham P.;
RT "HLA-Bw22: a family of molecules with identity to HLA-B7 in the alpha 1-
RT helix.";
RL J. Immunol. 148:1155-1162(1992).
RN [4]
RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELES B*45:01; B*50:01 AND B*78:01).
RX PubMed=1431115;
RA Madrigal J.A., Belich M.P., Hildebrand W.H., Benjamin R.J., Little A.-M.,
RA Zemmour J., Ennis P.D., Ward F.E., Petzl-Erler M.L., Martell R.W.,
RA du Toit E.D., Parham P.;
RT "Distinctive HLA-A,B antigens of black populations formed by interallelic
RT conversion.";
RL J. Immunol. 149:3411-3415(1992).
RN [5]
RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*49:01).
RX PubMed=1385528;
RA Hildebrand W.H., Madrigal J.A., Belich M.P., Zemmour J., Ward F.E.,
RA Williams R.C., Parham P.;
RT "Serologic cross-reactivities poorly reflect allelic relationships in the
RT HLA-B12 and HLA-B21 groups. Dominant epitopes of the alpha 2 helix.";
RL J. Immunol. 149:3563-3568(1992).
RN [6]
RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*48:01).
RX PubMed=1317015; DOI=10.1038/357326a0;
RA Belich M.P., Madrigal J.A., Hildebrand W.H., Zemmour J., Williams R.C.,
RA Luz R., Petzl-Erler M.L., Parham P.;
RT "Unusual HLA-B alleles in two tribes of Brazilian Indians.";
RL Nature 357:326-329(1992).
RN [7]
RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*40:02).
RX PubMed=1362296; DOI=10.1111/j.1399-0039.1992.tb02053.x;
RA Domena J.D., Johnston-Dow L., Parham P.;
RT "The B*4002 allele encodes the B61 antigen: B40* is identical to B61.";
RL Tissue Antigens 40:254-256(1992).
RN [8]
RP NUCLEOTIDE SEQUENCE [MRNA] OF 13-318 (ALLELE B*40:02).
RC TISSUE=Blood;
RX PubMed=1481202; DOI=10.1111/j.1399-0039.1992.tb02054.x;
RA Lin L., Watanabe Y., Tokunaga K., Kuwata S., Kohsaka T., Akaza T.;
RT "A common Japanese haplotype HLA-A26-Cw3-B61-DR9-DQ3 carries HLA-B*4002.";
RL Tissue Antigens 40:257-260(1992).
RN [9]
RP NUCLEOTIDE SEQUENCE [MRNA] OF 25-362 (ALLELE B*15:01).
RX PubMed=8423049; DOI=10.1007/bf00216833;
RA Choo S.Y., Fan L.A., Hansen J.A.;
RT "Allelic variations clustered in the antigen binding sites of HLA-Bw62
RT molecules.";
RL Immunogenetics 37:108-113(1993).
RN [10]
RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*59:01).
RX PubMed=8362411; DOI=10.1111/j.1399-0039.1993.tb02001.x;
RA Hildebrand W.H., Domena J.D., Parham P.;
RT "Primary structure shows HLA-B59 to be a hybrid of HLA-B55 and HLA-B51, and
RT not a subtype of HLA-B8.";
RL Tissue Antigens 41:190-195(1993).
RN [11]
RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*73:01).
RX PubMed=7517915; DOI=10.1007/bf00188185;
RA Vilches C., de Pablo R., Herrero M.J., Moreno M.E., Kreisler M.;
RT "HLA-B73: an atypical HLA-B molecule carrying a Bw6-epitope motif variant
RT and a B pocket identical to HLA-B27.";
RL Immunogenetics 40:166-166(1994).
RN [12]
RP NUCLEOTIDE SEQUENCE [MRNA] OF 25-362 (ALLELE B*15:01).
RX PubMed=7521976; DOI=10.1111/j.1399-0039.1994.tb02327.x;
RA Hildebrand W.H., Domena J.D., Shen S.Y., Lau M., Terasaki P.I., Bunce M.,
RA Marsh S.G.E., Guttridge M.G., Bias W.B., Parham P.;
RT "HLA-B15: a widespread and diverse family of HLA-B alleles.";
RL Tissue Antigens 43:209-218(1994).
RN [13]
RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*73:01).
RX PubMed=7524186; DOI=10.1111/j.1399-0039.1994.tb02344.x;
RA Parham P., Arnett K.L., Adams E.J., Barber L.D., Domena J.D., Stewart D.,
RA Hildebrand W.H., Little A.-M.;
RT "The HLA-B73 antigen has a most unusual structure that defines a second
RT lineage of HLA-B alleles.";
RL Tissue Antigens 43:302-313(1994).
RN [14]
RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*73:01).
RX PubMed=8547229; DOI=10.1111/j.1744-313x.1995.tb00237.x;
RA Hoffmann H.J., Kristensen T.J., Jensen T.G., Graugaard B., Lamm L.U.;
RT "Antigenic characteristics and cDNA sequences of HLA-B73.";
RL Eur. J. Immunogenet. 22:231-240(1995).
RN [15]
RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*13:02).
RC TISSUE=Blood;
RX PubMed=7558929; DOI=10.1016/0198-8859(94)00120-f;
RA Lin L., Tokunaga K., Nakajima F., Ishikawa Y., Kashiwase K., Tanaka H.,
RA Kuwata S., Sideltseva E., Akaza T., Tadokoro K., Shibata Y.,
RA Chandanayingyong D., Juji T.;
RT "Both HLA-B*1301 and B*1302 exist in Asian populations and are associated
RT with different haplotypes.";
RL Hum. Immunol. 43:51-56(1995).
RN [16]
RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*81:01).
RX PubMed=8847228; DOI=10.1016/0198-8859(95)00082-f;
RA Ellexson M.E., Zhang G., Stewart D., Lau M., Teresi G., Terasaki P.,
RA Roe B.A., Hildebrand W.H.;
RT "Nucleotide sequence analysis of HLA-B*1523 and B*8101. Dominant alpha-
RT helical motifs produce complex serologic recognition patterns for the HLA-
RT B''DT'' and HLA-B''NM5'' antigens.";
RL Hum. Immunol. 44:103-110(1995).
RN [17]
RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELES B*38:01 AND B*39:02).
RX PubMed=7725307; DOI=10.1111/j.1399-0039.1995.tb02410.x;
RA Adams E.J., Martinez-Naves E., Arnett K.L., Little A.-M., Tyan D.B.,
RA Parham P.;
RT "HLA-B16 antigens: sequence of the ST-16 antigen, further definition of two
RT B38 subtypes and evidence for convergent evolution of B*3902.";
RL Tissue Antigens 45:18-26(1995).
RN [18]
RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*81:01).
RX PubMed=8851728; DOI=10.1111/j.1399-0039.1996.tb02527.x;
RA Vilches C., Sanz L., de Pablo R., Moreno M.E., Puente S., Kreisler M.;
RT "Molecular characterization of the new alleles HLA-B*8101 and B*4407.";
RL Tissue Antigens 47:139-142(1996).
RN [19]
RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*82:01).
RX PubMed=8740766; DOI=10.1111/j.1399-0039.1996.tb02538.x;
RA Hurley C.K., Steiner N.K., Hoyer R.J., Menchaca E., Mitton W., Simonis T.,
RA Hartzman R.J., Johnson A.H., Ng J.;
RT "Novel HLA-B alleles, B*8201, B*3515 and B*5106, add to the complexity of
RT serologic identification of HLA types.";
RL Tissue Antigens 47:179-187(1996).
RN [20]
RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*15:01).
RC TISSUE=Blood;
RX PubMed=8773315; DOI=10.1111/j.1399-0039.1996.tb02553.x;
RA Lin L., Tokunaga K., Tanaka H., Nakajima F., Imanishi T., Kashiwase K.,
RA Bannai M., Mizuno S., Akaza T., Tadokoro K., Shibata Y., Juji T.;
RT "Further molecular diversity in the HLA-B15 group.";
RL Tissue Antigens 47:265-274(1996).
RN [21]
RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*58:01).
RX PubMed=10395103; DOI=10.1034/j.1399-0039.1999.530603.x;
RA Inoue T., Ogawa A., Tokunaga K., Ishikawa Y., Kashiwase K., Tanaka H.,
RA Park M.H., Jia G.J., Chimge N.-O., Sideltseva E.W., Akaza T., Tadokoro K.,
RA Takahashi T., Juji T.;
RT "Diversity of HLA-B17 alleles and haplotypes in East Asians and a novel Cw6
RT allele (Cw*0604) associated with B*5701.";
RL Tissue Antigens 53:534-544(1999).
RN [22]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*58:01).
RX PubMed=2995352; DOI=10.1016/s0021-9258(17)38967-6;
RA Ways J.P., Coppin H.L., Parham P.;
RT "The complete primary structure of HLA-Bw58.";
RL J. Biol. Chem. 260:11924-11933(1985).
RN [23]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELES B*27:05).
RX PubMed=3011411; DOI=10.1002/j.1460-2075.1986.tb04245.x;
RA Seemann G.H.A., Rein R.S., Brown C.S., Ploegh H.L.;
RT "Gene conversion-like mechanisms may generate polymorphism in human class I
RT genes.";
RL EMBO J. 5:547-552(1986).
RN [24]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 25-298 (ALLELE B*27:05).
RX PubMed=3489755;
RA Coppin H.L., McDevitt H.O.;
RT "Absence of polymorphism between HLA-B27 genomic exon sequences isolated
RT from normal donors and ankylosing spondylitis patients.";
RL J. Immunol. 137:2168-2172(1986).
RN [25]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*13:02 AND B*47:01).
RX PubMed=3257938; DOI=10.1007/bf00376123;
RA Zemmour J., Ennis P.D., Parham P., Dupont B.;
RT "Comparison of the structure of HLA-Bw47 to HLA-B13 and its relationship to
RT 21-hydroxylase deficiency.";
RL Immunogenetics 27:281-287(1988).
RN [26]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*35:01).
RX PubMed=2788131; DOI=10.1007/bf02421534;
RA Ooba T., Hayashi H., Karaki S., Tanabe M., Kano K., Takiguchi M.;
RT "The structure of HLA-B35 suggests that it is derived from HLA-Bw58 by two
RT genetic mechanisms.";
RL Immunogenetics 30:76-80(1989).
RN [27]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*51:01).
RX PubMed=2714852; DOI=10.1007/bf00352839;
RA Pohla H., Kuon W., Tabaczewski P., Doerner C., Weiss E.H.;
RT "Allelic variation in HLA-B and HLA-C sequences and the evolution of the
RT HLA-B alleles.";
RL Immunogenetics 29:297-307(1989).
RN [28]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELES B*08:01; B*13:02; B*14:01;
RP B*18:01; B*41:01; B*42:01; B*44:02 AND B*46:01).
RX PubMed=2715640;
RA Parham P., Lawlor D.A., Lomen C.E., Ennis P.D.;
RT "Diversity and diversification of HLA-A,B,C alleles.";
RL J. Immunol. 142:3937-3950(1989).
RN [29]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*53:01).
RX PubMed=1699887; DOI=10.1007/bf02114973;
RA Hayashi H., Ooba T., Nakayama S., Sekimata M., Kano K., Takiguchi M.;
RT "Allospecificities between HLA-Bw53 and HLA-B35 are generated by
RT substitution of the residues associated with HLA-Bw4/Bw6 public epitopes.";
RL Immunogenetics 32:195-199(1990).
RN [30]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*78:01).
RX PubMed=1691230;
RA Sekimata M., Hiraiwa M., Andrien M., Dupont E., Karaki S., Yamamoto J.,
RA Kano K., Takiguchi M.;
RT "Allodeterminants and evolution of a novel HLA-B5 CREG antigen, HLA-B
RT SNA.";
RL J. Immunol. 144:3228-3233(1990).
RN [31]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*57:01).
RX PubMed=2251138; DOI=10.1093/nar/18.22.6702;
RA Isamat M., Girdlestone J., Milstein C.;
RT "Nucleotide sequence of an HLA-Bw57 gene.";
RL Nucleic Acids Res. 18:6702-6702(1990).
RN [32]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*39:02).
RX PubMed=8420828; DOI=10.1007/bf00191887;
RA Kato N., Karaki S., Kashiwase K., Mueller C., Akaza T., Juji T., Kano K.,
RA Takiguchi M.;
RT "Molecular analysis of HLA-B39 subtypes.";
RL Immunogenetics 37:212-216(1993).
RN [33]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*40:01), AND NUCLEOTIDE SEQUENCE
RP [MRNA] (ALLELE B*67:01).
RX PubMed=7517584; DOI=10.1111/j.1399-0039.1994.tb02294.x;
RA Little A.-M., Domena J.D., Hildebrand W.H., Shen S.Y., Barber L.D.,
RA Marsh S.G.E., Bias W.B., Parham P.;
RT "HLA-B67: a member of the HLA-B16 family that expresses the ME1 epitope.";
RL Tissue Antigens 43:38-43(1994).
RN [34]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELES B*07:02; B*08:01; B*18:01;
RP B*41:01; B*42:01; B*45:01; B*46:01; B*47:01; B*48:01 AND B*55:01).
RC TISSUE=Blood;
RX PubMed=12622774; DOI=10.1034/j.1399-0039.2003.610103.x;
RA Cox S.T., McWhinnie A.J., Robinson J., Marsh S.G.E., Parham P.,
RA Madrigal J.A., Little A.-M.;
RT "Cloning and sequencing full-length HLA-B and -C genes.";
RL Tissue Antigens 61:20-48(2003).
RN [35]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*52:01).
RX PubMed=21585707; DOI=10.1111/j.1744-313x.2011.01016.x;
RA Zhu F., He Y., Zhang W., He J., He J., Xu X., Lv H., Yan L.;
RT "Analysis for complete genomic sequence of HLA-B and HLA-C alleles in the
RT Chinese Han population.";
RL Int. J. Immunogenet. 38:281-284(2011).
RN [36]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*73:01).
RX PubMed=21868630; DOI=10.1126/science.1209202;
RA Abi-Rached L., Jobin M.J., Kulkarni S., McWhinnie A., Dalva K., Gragert L.,
RA Babrzadeh F., Gharizadeh B., Luo M., Plummer F.A., Kimani J.,
RA Carrington M., Middleton D., Rajalingam R., Beksac M., Marsh S.G.,
RA Maiers M., Guethlein L.A., Tavoularis S., Little A.M., Green R.E.,
RA Norman P.J., Parham P.;
RT "The shaping of modern human immune systems by multiregional admixture with
RT archaic humans.";
RL Science 334:89-94(2011).
RN [37]
RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-322 (ALLELE B*37:01), AND NUCLEOTIDE
RP SEQUENCE [MRNA] OF 1-322 (ALLELE B*50:01).
RA Hurley C.K., Bei M., Rodriguez S., Johnson A.;
RL Submitted (JUN-1994) to the EMBL/GenBank/DDBJ databases.
RN [38]
RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*59:01).
RC TISSUE=Blood;
RA Lin L., Tokunaga K.;
RL Submitted (APR-1995) to the EMBL/GenBank/DDBJ databases.
RN [39]
RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*07:02).
RA Ellexson M.E., Zhang L., Hildebrand W.H.;
RL Submitted (JUN-1995) to the EMBL/GenBank/DDBJ databases.
RN [40]
RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*82:01).
RA Ellexson M.E., Hildebrand W.H.;
RL Submitted (OCT-1995) to the EMBL/GenBank/DDBJ databases.
RN [41]
RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*38:01).
RA Morlighem G.;
RL Submitted (NOV-1995) to the EMBL/GenBank/DDBJ databases.
RN [42]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*44:02).
RA Dunn P.P.J.;
RT "Complete nucleotide sequencing of HLA class I genes.";
RL Submitted (MAR-2001) to the EMBL/GenBank/DDBJ databases.
RN [43]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*07:02).
RA Marsh S.G.E.;
RT "Intron sequences of HLA class I.";
RL Submitted (MAR-2001) to the EMBL/GenBank/DDBJ databases.
RN [44]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*37:01).
RC TISSUE=Blood;
RA Cox S.T.;
RT "Confirmation of B*3701.";
RL Submitted (APR-2001) to the EMBL/GenBank/DDBJ databases.
RN [45]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*78:01).
RC TISSUE=Blood;
RA Cox S.T.;
RT "Confirmation of B*7801.";
RL Submitted (APR-2001) to the EMBL/GenBank/DDBJ databases.
RN [46]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*27:01).
RA Lazaro A.M., Hou L., Enriquez E., Persaud M., Hurley C.K.;
RT "Oncology, C.W.Bill Young DoD Marrow Donor Recruitment and Research
RT Program, 11333 Woodglen Dr, Rockville, MD 20852, USA.";
RL Submitted (NOV-2017) to the EMBL/GenBank/DDBJ databases.
RN [47]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ALLELE B*55:01).
RC TISSUE=Leukemia;
RA Zhou J., Yu W., Tang H., Mei G., Tsang Y.T.M., Bouck J., Gibbs R.A.,
RA Margolin J.F.;
RT "Pediatric leukemia cDNA sequencing project.";
RL Submitted (JUL-2000) to the EMBL/GenBank/DDBJ databases.
RN [48]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] (ALLELE B*08:01).
RA Shiina S., Tamiya G., Oka A., Inoko H.;
RT "Homo sapiens 2,229,817bp genomic DNA of 6p21.3 HLA class I region.";
RL Submitted (SEP-1999) to the EMBL/GenBank/DDBJ databases.
RN [49]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC TISSUE=Brain;
RX PubMed=15489334; DOI=10.1101/gr.2596504;
RG The MGC Project Team;
RT "The status, quality, and expansion of the NIH full-length cDNA project:
RT the Mammalian Gene Collection (MGC).";
RL Genome Res. 14:2121-2127(2004).
RN [50]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ALLELE B*07:02).
RC TISSUE=Subthalamic nucleus;
RX PubMed=14702039; DOI=10.1038/ng1285;
RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA Isogai T., Sugano S.;
RT "Complete sequencing and characterization of 21,243 full-length human
RT cDNAs.";
RL Nat. Genet. 36:40-45(2004).
RN [51]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX PubMed=14574404; DOI=10.1038/nature02055;
RA Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA Rogers J., Beck S.;
RT "The DNA sequence and analysis of human chromosome 6.";
RL Nature 425:805-811(2003).
RN [52]
RP PROTEIN SEQUENCE OF 25-295 (B*07:02).
RX PubMed=518865; DOI=10.1021/bi00592a030;
RA Orr H.T., Lopez de Castro J.A., Lancet D., Strominger J.L.;
RT "Complete amino acid sequence of a papain-solubilized human
RT histocompatibility antigen, HLA-B7. 2. Sequence determination and search
RT for homologies.";
RL Biochemistry 18:5711-5720(1979).
RN [53]
RP FUNCTION (ALLELE B*27:05).
RX PubMed=1922338; DOI=10.1038/353326a0;
RA Jardetzky T.S., Lane W.S., Robinson R.A., Madden D.R., Wiley D.C.;
RT "Identification of self peptides bound to purified HLA-B27.";
RL Nature 353:326-329(1991).
RN [54]
RP FUNCTION (ALLELES B*07:02; B*54:01; B*55:01; B*56:01 AND B*67:01).
RX PubMed=7743181; DOI=10.1016/s0960-9822(95)00039-x;
RA Barber L.D., Gillece-Castro B., Percival L., Li X., Clayberger C.,
RA Parham P.;
RT "Overlap in the repertoires of peptides bound in vivo by a group of related
RT class I HLA-B allotypes.";
RL Curr. Biol. 5:179-190(1995).
RN [55]
RP FUNCTION (ALLELE B*27:05).
RX PubMed=8879234; DOI=10.1084/jem.184.4.1585;
RA Peruzzi M., Wagtmann N., Long E.O.;
RT "A p70 killer cell inhibitory receptor specific for several HLA-B allotypes
RT discriminates among peptides bound to HLA-B*2705.";
RL J. Exp. Med. 184:1585-1590(1996).
RN [56]
RP INTERACTION WITH B2M, AND INTERACTION WITH CALR AND TAP1-TAP2.
RX PubMed=9036970;
RA Solheim J.C., Harris M.R., Kindle C.S., Hansen T.H.;
RT "Prominence of beta 2-microglobulin, class I heavy chain conformation, and
RT tapasin in the interactions of class I heavy chain with calreticulin and
RT the transporter associated with antigen processing.";
RL J. Immunol. 158:2236-2241(1997).
RN [57]
RP FUNCTION (ALLELES B*08:01; B*27:05 AND B*44:02), INTERACTION WITH
RP TAP1-TAP2, AND SUBCELLULAR LOCATION.
RX PubMed=9620674; DOI=10.1016/s1074-7613(00)80558-0;
RA Peh C.A., Burrows S.R., Barnden M., Khanna R., Cresswell P., Moss D.J.,
RA McCluskey J.;
RT "HLA-B27-restricted antigen presentation in the absence of tapasin reveals
RT polymorphism in mechanisms of HLA class I peptide loading.";
RL Immunity 8:531-542(1998).
RN [58]
RP INTERACTION WITH HTLV-1 ACCESSORY PROTEIN P12I (MICROBIAL INFECTION).
RX PubMed=11390610; DOI=10.1128/jvi.75.13.6086-6094.2001;
RA Johnson J.M., Nicot C., Fullen J., Ciminale V., Casareto L., Mulloy J.C.,
RA Jacobson S., Franchini G.;
RT "Free major histocompatibility complex class I heavy chain is
RT preferentially targeted for degradation by human T-cell
RT leukemia/lymphotropic virus type 1 p12(I) protein.";
RL J. Virol. 75:6086-6094(2001).
RN [59]
RP FUNCTION (ALLELE B*18:01).
RX PubMed=12366779; DOI=10.1034/j.1399-0039.2002.600103.x;
RA Bilsborough J., Panichelli C., Duffour M.T., Warnier G., Lurquin C.,
RA Schultz E.S., Thielemans K., Corthals J., Boon T., van der Bruggen P.;
RT "A MAGE-3 peptide presented by HLA-B44 is also recognized by cytolytic T
RT lymphocytes on HLA-B18.";
RL Tissue Antigens 60:16-24(2002).
RN [60]
RP FUNCTION (ALLELE B*18:01).
RX PubMed=14978097; DOI=10.4049/jimmunol.172.5.2944;
RA Hickman H.D., Luis A.D., Buchli R., Few S.R., Sathiamurthy M.,
RA VanGundy R.S., Giberson C.F., Hildebrand W.H.;
RT "Toward a definition of self: proteomic evaluation of the class I peptide
RT repertoire.";
RL J. Immunol. 172:2944-2952(2004).
RN [61]
RP FUNCTION (ALLELE B*27:05).
RX PubMed=15113903; DOI=10.1128/jvi.78.10.5216-5222.2004;
RA Berkhoff E.G., Boon A.C., Nieuwkoop N.J., Fouchier R.A., Sintnicolaas K.,
RA Osterhaus A.D., Rimmelzwaan G.F.;
RT "A mutation in the HLA-B*2705-restricted NP383-391 epitope affects the
RT human influenza A virus-specific cytotoxic T-lymphocyte response in
RT vitro.";
RL J. Virol. 78:5216-5222(2004).
RN [62]
RP FUNCTION (ALLELE B*13:02).
RX PubMed=17251285; DOI=10.1128/jvi.02689-06;
RA Honeyborne I., Prendergast A., Pereyra F., Leslie A., Crawford H.,
RA Payne R., Reddy S., Bishop K., Moodley E., Nair K., van der Stok M.,
RA McCarthy N., Rousseau C.M., Addo M., Mullins J.I., Brander C., Kiepiela P.,
RA Walker B.D., Goulder P.J.;
RT "Control of human immunodeficiency virus type 1 is associated with HLA-B*13
RT and targeting of multiple gag-specific CD8+ T-cell epitopes.";
RL J. Virol. 81:3667-3672(2007).
RN [63]
RP FUNCTION (ALLELES B*18:01; B*40:01; B*41:01; B*44:02; B*45:01; B*47:01;
RP B*49:01 AND B*50:01).
RX PubMed=18991276; DOI=10.1002/eji.200838632;
RA Hillen N., Mester G., Lemmel C., Weinzierl A.O., Mueller M., Wernet D.,
RA Hennenlotter J., Stenzl A., Rammensee H.G., Stevanovic S.;
RT "Essential differences in ligand presentation and T cell epitope
RT recognition among HLA molecules of the HLA-B44 supertype.";
RL Eur. J. Immunol. 38:2993-3003(2008).
RN [64]
RP FUNCTION (ALLELE B*27:05).
RX PubMed=18385228; DOI=10.1128/jvi.02356-07;
RA Schneidewind A., Brockman M.A., Sidney J., Wang Y.E., Chen H.,
RA Suscovich T.J., Li B., Adam R.I., Allgaier R.L., Mothe B.R., Kuntzen T.,
RA Oniangue-Ndza C., Trocha A., Yu X.G., Brander C., Sette A., Walker B.D.,
RA Allen T.M.;
RT "Structural and functional constraints limit options for cytotoxic T-
RT lymphocyte escape in the immunodominant HLA-B27-restricted epitope in human
RT immunodeficiency virus type 1 capsid.";
RL J. Virol. 82:5594-5605(2008).
RN [65]
RP FUNCTION (ALLELE B*27:05).
RX PubMed=19139562; DOI=10.1172/jci36587;
RA Dazert E., Neumann-Haefelin C., Bressanelli S., Fitzmaurice K., Kort J.,
RA Timm J., McKiernan S., Kelleher D., Gruener N., Tavis J.E., Rosen H.R.,
RA Shaw J., Bowness P., Blum H.E., Klenerman P., Bartenschlager R., Thimme R.;
RT "Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV
RT escape from a protective HLA-B27-restricted human immune response.";
RL J. Clin. Invest. 119:376-386(2009).
RN [66]
RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-110.
RC TISSUE=Liver;
RX PubMed=19159218; DOI=10.1021/pr8008012;
RA Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT "Glycoproteomics analysis of human liver tissue by combination of multiple
RT enzyme digestion and hydrazide chemistry.";
RL J. Proteome Res. 8:651-661(2009).
RN [67]
RP NOMENCLATURE.
RX PubMed=20356336; DOI=10.1111/j.1399-0039.2010.01466.x;
RA Marsh S.G., Albert E.D., Bodmer W.F., Bontrop R.E., Dupont B., Erlich H.A.,
RA Fernandez-Vina M., Geraghty D.E., Holdsworth R., Hurley C.K., Lau M.,
RA Lee K.W., Mach B., Maiers M., Mayr W.R., Mueller C.R., Parham P.,
RA Petersdorf E.W., Sasazuki T., Strominger J.L., Svejgaard A., Terasaki P.I.,
RA Tiercy J.M., Trowsdale J.;
RT "Nomenclature for factors of the HLA system, 2010.";
RL Tissue Antigens 75:291-455(2010).
RN [68]
RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA Bennett K.L., Superti-Furga G., Colinge J.;
RT "Initial characterization of the human central proteome.";
RL BMC Syst. Biol. 5:17-17(2011).
RN [69]
RP FUNCTION.
RX PubMed=23209413; DOI=10.1371/journal.ppat.1003042;
RA Schmidt J., Iversen A.K., Tenzer S., Gostick E., Price D.A., Lohmann V.,
RA Distler U., Bowness P., Schild H., Blum H.E., Klenerman P.,
RA Neumann-Haefelin C., Thimme R.;
RT "Rapid antigen processing and presentation of a protective and
RT immunodominant HLA-B*27-restricted hepatitis C virus-specific CD8+ T-cell
RT epitope.";
RL PLoS Pathog. 8:E1003042-E1003042(2012).
RN [70]
RP FUNCTION (ALLELE B*18:01).
RX PubMed=23749632; DOI=10.4049/jimmunol.1300292;
RA Rist M.J., Theodossis A., Croft N.P., Neller M.A., Welland A., Chen Z.,
RA Sullivan L.C., Burrows J.M., Miles J.J., Brennan R.M., Gras S., Khanna R.,
RA Brooks A.G., McCluskey J., Purcell A.W., Rossjohn J., Burrows S.R.;
RT "HLA peptide length preferences control CD8+ T cell responses.";
RL J. Immunol. 191:561-571(2013).
RN [71]
RP INTERACTION WITH TAPBPL, AND SUBCELLULAR LOCATION.
RX PubMed=26439010; DOI=10.7554/elife.09617;
RA Hermann C., van Hateren A., Trautwein N., Neerincx A., Duriez P.J.,
RA Stevanovic S., Trowsdale J., Deane J.E., Elliott T., Boyle L.H.;
RT "TAPBPR alters MHC class I peptide presentation by functioning as a peptide
RT exchange catalyst.";
RL Elife 4:0-0(2015).
RN [72]
RP FUNCTION (ALLELES B*08:01 AND B*57:01), DOMAIN, BW4 AND BW6 MOTIFS,
RP INTERACTION WITH KIR3DL1, SUBCELLULAR LOCATION, AND CHARACTERIZATION OF
RP VARIANTS ILE-104 AND ARG-107.
RX PubMed=25480565; DOI=10.4049/jimmunol.1402542;
RA Saunders P.M., Vivian J.P., Baschuk N., Beddoe T., Widjaja J.,
RA O'Connor G.M., Hitchen C., Pymm P., Andrews D.M., Gras S., McVicar D.W.,
RA Rossjohn J., Brooks A.G.;
RT "The interaction of KIR3DL1*001 with HLA class I molecules is dependent
RT upon molecular microarchitecture within the Bw4 epitope.";
RL J. Immunol. 194:781-789(2015).
RN [73]
RP INTERACTION WITH THE PEPTIDE-LOADING COMPLEX.
RX PubMed=26416272; DOI=10.4049/jimmunol.1501515;
RA Fleischmann G., Fisette O., Thomas C., Wieneke R., Tumulka F.,
RA Schneeweiss C., Springer S., Schaefer L.V., Tampe R.;
RT "Mechanistic Basis for Epitope Proofreading in the Peptide-Loading
RT Complex.";
RL J. Immunol. 195:4503-4513(2015).
RN [74]
RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX PubMed=25944712; DOI=10.1002/pmic.201400617;
RA Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT "N-terminome analysis of the human mitochondrial proteome.";
RL Proteomics 15:2519-2524(2015).
RN [75]
RP FUNCTION (ALLELE B*46:01), AND INTERACTION WITH KIR2DL3.
RX PubMed=28514659; DOI=10.1016/j.celrep.2017.04.059;
RA Hilton H.G., McMurtrey C.P., Han A.S., Djaoud Z., Guethlein L.A.,
RA Blokhuis J.H., Pugh J.L., Goyos A., Horowitz A., Buchli R., Jackson K.W.,
RA Bardet W., Bushnell D.A., Robinson P.J., Mendoza J.L., Birnbaum M.E.,
RA Nielsen M., Garcia K.C., Hildebrand W.H., Parham P.;
RT "The Intergenic Recombinant HLA-B*46:01 Has a Distinctive Peptidome that
RT Includes KIR2DL3 Ligands.";
RL Cell Rep. 19:1394-1405(2017).
RN [76]
RP FUNCTION (ALLELES B*07:02; B*27:05 AND B*40:01).
RX PubMed=32887977; DOI=10.1038/s41590-020-0782-6;
RG Oxford Immunology Network Covid-19 Response T cell Consortium;
RG ISARIC4C Investigators;
RA Peng Y., Mentzer A.J., Liu G., Yao X., Yin Z., Dong D., Dejnirattisai W.,
RA Rostron T., Supasa P., Liu C., Lopez-Camacho C., Slon-Campos J., Zhao Y.,
RA Stuart D.I., Paesen G.C., Grimes J.M., Antson A.A., Bayfield O.W.,
RA Hawkins D.E.D.P., Ker D.S., Wang B., Turtle L., Subramaniam K., Thomson P.,
RA Zhang P., Dold C., Ratcliff J., Simmonds P., de Silva T., Sopp P.,
RA Wellington D., Rajapaksa U., Chen Y.L., Salio M., Napolitani G., Paes W.,
RA Borrow P., Kessler B.M., Fry J.W., Schwabe N.F., Semple M.G., Baillie J.K.,
RA Moore S.C., Openshaw P.J.M., Ansari M.A., Dunachie S., Barnes E.,
RA Frater J., Kerr G., Goulder P., Lockett T., Levin R., Zhang Y., Jing R.,
RA Ho L.P., Cornall R.J., Conlon C.P., Klenerman P., Screaton G.R.,
RA Mongkolsapaya J., McMichael A., Knight J.C., Ogg G., Dong T.;
RT "Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK
RT convalescent individuals following COVID-19.";
RL Nat. Immunol. 21:1336-1345(2020).
RN [77]
RP FUNCTION (ALLELE B*57:01).
RX PubMed=34228645; DOI=10.1172/jci148979;
RA Bansal A., Gehre M.N., Qin K., Sterrett S., Ali A., Dang Y., Abraham S.,
RA Costanzo M.C., Venegas L.A., Tang J., Manjunath N., Brockman M.A.,
RA Yang O.O., Kan-Mitchell J., Goepfert P.A.;
RT "HLA-E-restricted HIV-1-specific CD8+ T cell responses in natural
RT infection.";
RL J. Clin. Invest. 131:0-0(2021).
RN [78]
RP DOMAIN, AND POLYMORPHISM.
RX PubMed=37264229; DOI=10.1038/s41590-023-01523-z;
RA Lin Z., Bashirova A.A., Viard M., Garner L., Quastel M., Beiersdorfer M.,
RA Kasprzak W.K., Akdag M., Yuki Y., Ojeda P., Das S., Andresson T.,
RA Naranbhai V., Horowitz A., McMichael A.J., Hoelzemer A., Gillespie G.M.,
RA Garcia-Beltran W.F., Carrington M.;
RT "HLA class I signal peptide polymorphism determines the level of CD94/NKG2-
RT HLA-E-mediated regulation of effector cell responses.";
RL Nat. Immunol. 24:1087-1097(2023).
RN [79]
RP X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 25-300 (ALLELE B*27:05) IN
RP COMPLEX WITH B2M AND PEPTIDE, AND FUNCTION (ALLELE B*27:05).
RX PubMed=15657948; DOI=10.1002/eji.200425724;
RA Stewart-Jones G.B., di Gleria K., Kollnberger S., McMichael A.J.,
RA Jones E.Y., Bowness P.;
RT "Crystal structures and KIR3DL1 recognition of three immunodominant viral
RT peptides complexed to HLA-B*2705.";
RL Eur. J. Immunol. 35:341-351(2005).
RN [80]
RP X-RAY CRYSTALLOGRAPHY (1.79 ANGSTROMS) OF 25-300 (ALLELE B*15:01) IN
RP COMPLEX WITH EBV NUCLEAR ANTIGEN AND UBE2 PEPTIDES, AND DISULFIDE BONDS.
RX PubMed=17057332; DOI=10.1107/s0907444906027636;
RA Roder G., Blicher T., Justesen S., Johannesen B., Kristensen O.,
RA Kastrup J., Buus S., Gajhede M.;
RT "Crystal structures of two peptide-HLA-B*1501 complexes; structural
RT characterization of the HLA-B62 supertype.";
RL Acta Crystallogr. D 62:1300-1310(2006).
RN [81]
RP X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 25-299 (ALLELE B*57:01) IN
RP COMPLEX WITH B2M AND SELF-PEPTIDE, INTERACTION WITH KIR3DL1, DOMAIN, BW4
RP MOTIF, AND FUNCTION (ALLELE B*57:01).
RX PubMed=22020283; DOI=10.1038/nature10517;
RA Vivian J.P., Duncan R.C., Berry R., O'Connor G.M., Reid H.H., Beddoe T.,
RA Gras S., Saunders P.M., Olshina M.A., Widjaja J.M., Harpur C.M., Lin J.,
RA Maloveste S.M., Price D.A., Lafont B.A., McVicar D.W., Clements C.S.,
RA Brooks A.G., Rossjohn J.;
RT "Killer cell immunoglobulin-like receptor 3DL1-mediated recognition of
RT human leukocyte antigen B.";
RL Nature 479:401-405(2011).
RN [82]
RP X-RAY CRYSTALLOGRAPHY (2.99 ANGSTROMS) OF 25-300 (ALLELE B*51:01) IN
RP COMPLEX WITH B2M AND PEPTIDE, INTERACTION WITH TCR, AND FUNCTION (ALLELE
RP B*51:01).
RX PubMed=24600035; DOI=10.4049/jimmunol.1302667;
RA Motozono C., Kuse N., Sun X., Rizkallah P.J., Fuller A., Oka S., Cole D.K.,
RA Sewell A.K., Takiguchi M.;
RT "Molecular basis of a dominant T cell response to an HIV reverse
RT transcriptase 8-mer epitope presented by the protective allele HLA-
RT B*51:01.";
RL J. Immunol. 192:3428-3434(2014).
RN [83]
RP X-RAY CRYSTALLOGRAPHY (1.59 ANGSTROMS) OF 25-300 (ALLELE B*07:02) IN
RP COMPLEX WITH B2M AND HIV-1 PEPTIDES, DISULFIDE BOND, FUNCTION (ALLELE
RP B*07:02), AND DOMAIN.
RX PubMed=25808313; DOI=10.1186/s12977-015-0149-5;
RA Kloverpris H.N., Cole D.K., Fuller A., Carlson J., Beck K.,
RA Schauenburg A.J., Rizkallah P.J., Buus S., Sewell A.K., Goulder P.;
RT "A molecular switch in immunodominant HIV-1-specific CD8 T-cell epitopes
RT shapes differential HLA-restricted escape.";
RL Retrovirology 12:20-20(2015).
RN [84]
RP X-RAY CRYSTALLOGRAPHY (1.50 ANGSTROMS) (ALLELE B*07:02) IN COMPLEX WITH B2M
RP AND PEPTIDE, DISULFIDE BOND, INTERACTION WITH TCR, AND FUNCTION (ALLELE
RP B*07:02).
RX PubMed=29531227; DOI=10.1038/s41467-018-03321-w;
RA Chan K.F., Gully B.S., Gras S., Beringer D.X., Kjer-Nielsen L., Cebon J.,
RA McCluskey J., Chen W., Rossjohn J.;
RT "Divergent T-cell receptor recognition modes of a HLA-I restricted extended
RT tumour-associated peptide.";
RL Nat. Commun. 9:1026-1026(2018).
RN [85]
RP ASSOCIATION WITH ABACAVIR HYPERSENSITIVITY.
RX PubMed=11888582; DOI=10.1016/s0140-6736(02)07873-x;
RA Mallal S., Nolan D., Witt C., Masel G., Martin A.M., Moore C., Sayer D.,
RA Castley A., Mamotte C., Maxwell D., James I., Christiansen F.T.;
RT "Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and
RT hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.";
RL Lancet 359:727-732(2002).
RN [86]
RP ASSOCIATION WITH SPDA1, AND POSSIBLE PROTECTIVE ROLE OF ALLELE B*27:07.
RX PubMed=15603872; DOI=10.1016/j.humimm.2004.08.177;
RA Varnavidou-Nicolaidou A., Karpasitou K., Georgiou D., Stylianou G.,
RA Kokkofitou A., Michalis C., Constantina C., Gregoriadou C., Kyriakides G.;
RT "HLA-B27 in the Greek Cypriot population: distribution of subtypes in
RT patients with ankylosing spondylitis and other HLA-B27-related diseases.
RT The possible protective role of B*2707.";
RL Hum. Immunol. 65:1451-1454(2004).
RN [87]
RP ASSOCIATION OF ALLELE B*15:02 WITH STEVENS-JOHNSON SYNDROME.
RX PubMed=15057820; DOI=10.1038/428486a;
RA Chung W.-H., Hung S.-I., Hong H.-S., Hsih M.-S., Yang L.-C., Ho H.-C.,
RA Wu J.-Y., Chen Y.-T.;
RT "Medical genetics: a marker for Stevens-Johnson syndrome.";
RL Nature 428:486-486(2004).
RN [88]
RP INVOLVEMENT IN RA, ASSOCIATION OF ALLELE GROUP B*8 WITH RHEUMATOID
RP ARTHRITIS, AND VARIANT ASP-33.
RX PubMed=22286218; DOI=10.1038/ng.1076;
RA Raychaudhuri S., Sandor C., Stahl E.A., Freudenberg J., Lee H.S., Jia X.,
RA Alfredsson L., Padyukov L., Klareskog L., Worthington J., Siminovitch K.A.,
RA Bae S.C., Plenge R.M., Gregersen P.K., de Bakker P.I.;
RT "Five amino acids in three HLA proteins explain most of the association
RT between MHC and seropositive rheumatoid arthritis.";
RL Nat. Genet. 44:291-296(2012).
RN [89]
RP ASSOCIATION OF ALLELE GROUP B*51 WITH BEHCET DISEASE.
RX PubMed=23291587; DOI=10.1038/ng.2520;
RA Kirino Y., Bertsias G., Ishigatsubo Y., Mizuki N., Tugal-Tutkun I.,
RA Seyahi E., Ozyazgan Y., Sacli F.S., Erer B., Inoko H., Emrence Z.,
RA Cakar A., Abaci N., Ustek D., Satorius C., Ueda A., Takeno M., Kim Y.,
RA Wood G.M., Ombrello M.J., Meguro A., Guel A., Remmers E.F., Kastner D.L.;
RT "Genome-wide association analysis identifies new susceptibility loci for
RT Behcet's disease and epistasis between HLA-B*51 and ERAP1.";
RL Nat. Genet. 45:202-207(2013).
RN [90]
RP POLYMORPHISM.
RX PubMed=28650991; DOI=10.1371/journal.pgen.1006862;
RA Robinson J., Guethlein L.A., Cereb N., Yang S.Y., Norman P.J.,
RA Marsh S.G.E., Parham P.;
RT "Distinguishing functional polymorphism from random variation in the
RT sequences of >10,000 HLA-A, -B and -C alleles.";
RL PLoS Genet. 13:E1006862-E1006862(2017).
CC -!- FUNCTION: Antigen-presenting major histocompatibility complex class I
CC (MHCI) molecule. In complex with B2M/beta 2 microglobulin displays
CC primarily viral and tumor-derived peptides on antigen-presenting cells
CC for recognition by alpha-beta T cell receptor (TCR) on HLA-B-restricted
CC CD8-positive T cells, guiding antigen-specific T cell immune response
CC to eliminate infected or transformed cells (PubMed:25808313,
CC PubMed:29531227, PubMed:9620674, PubMed:23209413). May also present
CC self-peptides derived from the signal sequence of secreted or membrane
CC proteins, although T cells specific for these peptides are usually
CC inactivated to prevent autoreactivity (PubMed:7743181,
CC PubMed:18991276). Both the peptide and the MHC molecule are recognized
CC by TCR, the peptide is responsible for the fine specificity of antigen
CC recognition and MHC residues account for the MHC restriction of T cells
CC (PubMed:29531227, PubMed:9620674, PubMed:24600035). Typically presents
CC intracellular peptide antigens of 8 to 13 amino acids that arise from
CC cytosolic proteolysis via constitutive proteasome and IFNG-induced
CC immunoproteasome (PubMed:23209413). Can bind different peptides
CC containing allele-specific binding motifs, which are mainly defined by
CC anchor residues at position 2 and 9 (PubMed:25808313, PubMed:29531227).
CC {ECO:0000269|PubMed:18991276, ECO:0000269|PubMed:23209413,
CC ECO:0000269|PubMed:24600035, ECO:0000269|PubMed:25808313,
CC ECO:0000269|PubMed:29531227, ECO:0000269|PubMed:7743181,
CC ECO:0000269|PubMed:9620674}.
CC -!- FUNCTION: Allele B*07:02: Displays peptides sharing a common signature
CC motif, namely a Pro residue at position 2 and mainly a Leu anchor
CC residue at the C-terminus (PubMed:7743181). Presents a long peptide
CC (APRGPHGGAASGL) derived from the cancer-testis antigen CTAG1A/NY-ESO-1,
CC eliciting a polyclonal CD8-positive T cell response against tumor cells
CC (PubMed:29531227). Presents viral epitopes derived from HIV-1 gag-pol
CC (TPQDLNTML) and Nef (RPQVPLRPM) (PubMed:25808313). Presents an
CC immunodominant epitope derived from SARS-CoV-2 N/nucleoprotein
CC (SPRWYFYYL) (PubMed:32887977). Displays self-peptides including a
CC peptide derived from the signal sequence of HLA-DPB1 (APRTVALTA)
CC (PubMed:7743181). {ECO:0000269|PubMed:25808313,
CC ECO:0000269|PubMed:29531227, ECO:0000269|PubMed:32887977,
CC ECO:0000269|PubMed:7743181}.
CC -!- FUNCTION: Allele B*08:01: Presents to CD8-positive T cells viral
CC epitopes derived from EBV/HHV-4 EBNA3 (QAKWRLQTL), eliciting cytotoxic
CC T cell response. {ECO:0000269|PubMed:9620674}.
CC -!- FUNCTION: Allele B*13:02: Presents multiple HIV-1 epitopes derived from
CC gag (RQANFLGKI, GQMREPRGSDI), nef (RQDILDLWI), gag-pol (RQYDQILIE,
CC GQGQWTYQI) and rev (LQLPPLERL), all having in common a Gln residue at
CC position 2 and mainly hydrophobic amino acids Leu, Ile or Val at the C-
CC terminus. Associated with succesful control of HIV-1 infection.
CC {ECO:0000269|PubMed:17251285}.
CC -!- FUNCTION: Allele B*18:01: Preferentially presents octomeric and
CC nonameric peptides sharing a common motif, namely a Glu at position 2
CC and Phe or Tyr anchor residues at the C-terminus (PubMed:14978097,
CC PubMed:23749632, PubMed:18991276). Presents an EBV/HHV-4 epitope
CC derived from BZLF1 (SELEIKRY) (PubMed:23749632). May present to CD8-
CC positive T cells an antigenic peptide derived from MAGEA3 (MEVDPIGHLY),
CC triggering an anti-tumor immune response (PubMed:12366779). May display
CC a broad repertoire of self-peptides with a preference for peptides
CC derived from RNA-binding proteins (PubMed:14978097).
CC {ECO:0000269|PubMed:12366779, ECO:0000269|PubMed:14978097,
CC ECO:0000269|PubMed:18991276, ECO:0000269|PubMed:23749632}.
CC -!- FUNCTION: Allele B*27:05: Presents to CD8-positive T cells
CC immunodominant viral epitopes derived from HCV POLG (ARMILMTHF), HIV-1
CC gag (KRWIILGLNK), IAV NP (SRYWAIRTR), SARS-CoV-2 N/nucleoprotein
CC (QRNAPRITF), EBV/HHV-4 EBNA4 (HRCQAIRKK) and EBV/HHV-4 EBNA6
CC (RRIYDLIEL), conferring longterm protection against viral infection
CC (PubMed:19139562, PubMed:18385228, PubMed:15113903, PubMed:9620674,
CC PubMed:32887977). Can present self-peptides derived from cytosolic and
CC nuclear proteins. All peptides carry an Arg at position 2
CC (PubMed:1922338). The peptide-bound form interacts with NK cell
CC inhibitory receptor KIR3DL1 and inhibits NK cell activation in a
CC peptide-specific way, being particularly sensitive to the nature of the
CC amino acid side chain at position 8 of the antigenic peptide
CC (PubMed:8879234, PubMed:15657948). KIR3DL1 fails to recognize HLA-
CC B*27:05 in complex with B2M and EBV/HHV-4 EBNA6 (RRIYDLIEL) peptide,
CC which can lead to increased activation of NK cells during infection
CC (PubMed:15657948). May present an altered repertoire of peptides in the
CC absence of TAP1-TAP2 and TAPBPL (PubMed:9620674).
CC {ECO:0000269|PubMed:15113903, ECO:0000269|PubMed:15657948,
CC ECO:0000269|PubMed:18385228, ECO:0000269|PubMed:19139562,
CC ECO:0000269|PubMed:1922338, ECO:0000269|PubMed:8879234,
CC ECO:0000269|PubMed:9620674}.
CC -!- FUNCTION: Allele B*40:01: Presents immunodominant viral epitopes
CC derived from EBV/HHV-4 LMP2 (IEDPPFNSL) and SARS-CoV-2 N/nucleoprotein
CC (MEVTPSGTWL), triggering memory CD8-positive T cell response
CC (PubMed:18991276, PubMed:32887977). Displays self-peptides sharing a
CC signature motif, namely a Glu at position 2 and a Leu anchor residue at
CC the C-terminus (PubMed:18991276). {ECO:0000269|PubMed:18991276,
CC ECO:0000269|PubMed:32887977}.
CC -!- FUNCTION: Allele B*41:01: Displays self-peptides sharing a signature
CC motif, namely a Glu at position 2 and Ala or Pro anchor residues at the
CC C-terminus. {ECO:0000269|PubMed:18991276}.
CC -!- FUNCTION: Allele B*44:02: Presents immunodominant viral epitopes
CC derived from EBV/HHV-4 EBNA4 (VEITPYKPTW) and EBNA6 (AEGGVGWRHW,
CC EENLLDFVRF), triggering memory CD8-positive T cell response
CC (PubMed:9620674, PubMed:18991276). Displays self-peptides sharing a
CC signature motif, namely a Glu at position 2 and Phe, Tyr or Trp anchor
CC residues at the C-terminus (PubMed:18991276).
CC {ECO:0000269|PubMed:18991276, ECO:0000269|PubMed:9620674}.
CC -!- FUNCTION: Allele B*45:01: Displays self-peptides sharing a signature
CC motif, namely a Glu at position 2 and Ala or Pro anchor residues at the
CC C-terminus. {ECO:0000269|PubMed:18991276}.
CC -!- FUNCTION: Allele B*46:01: Preferentially presents nonameric peptides
CC sharing a signature motif, namely Ala and Leu at position 2 and Tyr,
CC Phe, Leu, or Met anchor residues at the C-terminus. The peptide-bound
CC form interacts with KIR2DL3 and inhibits NK cell cytotoxic response in
CC a peptide-specific way. {ECO:0000269|PubMed:28514659}.
CC -!- FUNCTION: Allele B*47:01: Displays self-peptides sharing a signature
CC motif, namely an Asp at position 2 and Leu or Met anchor residues at
CC the C-terminus. {ECO:0000269|PubMed:18991276}.
CC -!- FUNCTION: Allele B*49:01: Displays self-peptides sharing a signature
CC motif, namely a Glu at position 2 and Ile or Val anchor residues at the
CC C-terminus. {ECO:0000269|PubMed:18991276}.
CC -!- FUNCTION: Allele B*50:01: Displays self-peptides sharing a signature
CC motif, namely a Glu at position 2 and Ala or Pro anchor residues at the
CC C-terminus. {ECO:0000269|PubMed:18991276}.
CC -!- FUNCTION: Allele B*51:01: Presents an octomeric HIV-1 epitope derived
CC from gag-pol (TAFTIPSI) to the public TRAV17/TRBV7-3 TCR clonotype,
CC strongly suppressing HIV-1 replication. {ECO:0000269|PubMed:24600035}.
CC -!- FUNCTION: Allele B*54:01: Displays peptides sharing a common signature
CC motif, namely a Pro residue at position 2 and Ala anchor residue at the
CC C-terminus. {ECO:0000269|PubMed:7743181}.
CC -!- FUNCTION: Allele B*55:01: Displays peptides sharing a common signature
CC motif, namely a Pro residue at position 2 and Ala anchor residue at the
CC C-terminus. {ECO:0000269|PubMed:7743181}.
CC -!- FUNCTION: Allele B*56:01: Displays peptides sharing a common signature
CC motif, namely a Pro residue at position 2 and Ala anchor residue at the
CC C-terminus. {ECO:0000269|PubMed:7743181}.
CC -!- FUNCTION: Allele B*57:01: The peptide-bound form recognizes KIR3DL1 and
CC inhibits NK cell cytotoxic response. Presents HIV gag peptides
CC (immunodominant KAFSPEVIPMF and subdominant KALGPAATL epitopes)
CC predominantly to CD8-positive T cell clones expressing a TRAV41-
CC containing TCR, triggering HLA-B-restricted T cell responses.
CC {ECO:0000269|PubMed:22020283, ECO:0000269|PubMed:25480565,
CC ECO:0000269|PubMed:34228645}.
CC -!- FUNCTION: Allele B*67:01: Displays peptides sharing a common signature
CC motif, namely a Pro residue at position 2 and Leu anchor residue at the
CC C-terminus. {ECO:0000269|PubMed:7743181}.
CC -!- SUBUNIT: Heterotrimer that consists of an alpha chain HLA-B, a beta
CC chain B2M and a peptide (peptide-HLA-B-B2M) (PubMed:25808313,
CC PubMed:29531227, PubMed:15657948, PubMed:17057332, PubMed:22020283,
CC PubMed:24600035). Early in biogenesis, HLA-B-B2M dimer interacts with
CC the components of the peptide-loading complex composed of TAPBP, TAP1-
CC TAP2, TAPBPL, PDIA3/ERP57 and CALR (PubMed:9036970, PubMed:9620674,
CC PubMed:26439010, PubMed:26416272). Interacts with TAP1-TAP2 transporter
CC via TAPBP; this interaction is obligatory for the loading of peptide
CC epitopes delivered to the ER by TAP1-TAP2 transporter (PubMed:9036970,
CC PubMed:9620674). Interacts with TAPBPL; TAPBPL binds peptide-free HLA-
CC B-B2M complexes or those loaded with low affinity peptides, likely
CC facilitating peptide exchange for higher affinity peptides
CC (PubMed:26439010). Only optimally assembled peptide-HLA-B-B2M trimer
CC translocates to the surface of antigen-presenting cells, where it
CC interacts with TCR and CD8 coreceptor on the surface of T cells. HLA-B
CC (via polymorphic alpha-1 and alpha-2 domains) interacts with antigen-
CC specific TCR (via CDR1, CDR2 and CDR3 domains) (PubMed:29531227,
CC PubMed:24600035). One HLA-B molecule (mainly via nonpolymorphic alpha-3
CC domain) interacts with one CD8A homodimer (via CDR-like loop); this
CC interaction ensures peptide-HLA-B-B2M recognition by CD8-positive T
CC cells only (PubMed:29531227). Allele B*57:01 interacts (via Bw4 motif)
CC with KIR3DL1 (via Ig-like C2-type domain); this interaction may
CC interfere with peptide binding (PubMed:22020283, PubMed:25480565).
CC Allele B*46:01 interacts with KIR2DL3 (PubMed:28514659).
CC {ECO:0000269|PubMed:15657948, ECO:0000269|PubMed:17057332,
CC ECO:0000269|PubMed:22020283, ECO:0000269|PubMed:24600035,
CC ECO:0000269|PubMed:25480565, ECO:0000269|PubMed:25808313,
CC ECO:0000269|PubMed:26416272, ECO:0000269|PubMed:26439010,
CC ECO:0000269|PubMed:28514659, ECO:0000269|PubMed:29531227,
CC ECO:0000269|PubMed:9036970, ECO:0000269|PubMed:9620674}.
CC -!- SUBUNIT: (Microbial infection) Interacts with HTLV-1 accessory protein
CC p12I. {ECO:0000269|PubMed:11390610}.
CC -!- INTERACTION:
CC P01889; P43626: KIR2DL1; NbExp=2; IntAct=EBI-1046513, EBI-8684277;
CC P01889; P43628: KIR2DL3; NbExp=2; IntAct=EBI-1046513, EBI-8632435;
CC P01889; P43632: KIR2DS4; NbExp=2; IntAct=EBI-1046513, EBI-13916812;
CC P01889; P43629: KIR3DL1; NbExp=3; IntAct=EBI-1046513, EBI-3910993;
CC P01889; Q14943: KIR3DS1; NbExp=7; IntAct=EBI-1046513, EBI-15316524;
CC P01889; Q8N423: LILRB2; NbExp=7; IntAct=EBI-1046513, EBI-2816428;
CC P01889; Q9BX59: TAPBPL; NbExp=3; IntAct=EBI-1046513, EBI-12017416;
CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:25480565,
CC ECO:0000269|PubMed:26439010, ECO:0000269|PubMed:9620674}; Single-pass
CC type I membrane protein {ECO:0000255}. Endoplasmic reticulum membrane
CC {ECO:0000305|PubMed:9620674}; Single-pass type I membrane protein
CC {ECO:0000255}.
CC -!- DOMAIN: The alpha-1 domain is a structural part of the peptide-binding
CC cleft (PubMed:25808313). Residues 101-107 determine Bw4/Bw6 motifs,
CC which serologically distinguish HLA-B alleles. Each HLA-B allele
CC posseses either the Bw4 or Bw6 motif. Only HLA-B alleles bearing the
CC Bw4 epitope are recognized by NK cell inhibitory receptor KIR3DL1
CC (PubMed:25480565, PubMed:22020283). {ECO:0000269|PubMed:22020283,
CC ECO:0000269|PubMed:25480565, ECO:0000269|PubMed:25808313}.
CC -!- DOMAIN: The alpha-2 domain is a structural part of the peptide-binding
CC cleft (PubMed:25808313). Mediates the interaction with TAP1-TAP2
CC complex (By similarity). {ECO:0000250|UniProtKB:P04439,
CC ECO:0000269|PubMed:25808313}.
CC -!- DOMAIN: The alpha-3 Ig-like domain mediates the interaction with CD8
CC coreceptor. {ECO:0000250|UniProtKB:P04439}.
CC -!- DOMAIN: The VL9 peptide/epitope (VMAPRT[V/L][L/V/I/F]L) derived from
CC the signal sequence is loaded onto HLA-E and enables HLA-E expression
CC at the plasma membrane. Distinct VL9 peptides presented by HLA-E
CC variably affect its recognition by KLRD1-KLRC1 or KLRD1-KLRC2 receptors
CC on NK cells. Most HLA-B allotypes contain VL9 peptides with low
CC affinity for HLA-E. The VL9 peptide derived from HLA-B*07, B*08, B*14,
CC B*38, B*39, B*42 and B*48 allotypes, displays high affinity for HLA-E
CC yet fails to drive NK cell activation. It outcompetes other VL9
CC peptides derived from HLA-A and HLA-C for binding to HLA-E, lowering
CC the threshold of NK cell activation. {ECO:0000269|PubMed:37264229}.
CC -!- POLYMORPHISM: The most polymorphic of the mammalian genome. Polymorphic
CC residues encode for alpha-1 and alpha-2 domains of the peptide-binding
CC cleft, where they contribute to variations in peptide binding and TCR
CC recognition among different alleles. The human population is estimated
CC to have millions of HLA-B alleles. But only 17 common HLA-A alleles are
CC considered core alleles, representing all functionally significant
CC variation (polymorphism) in alpha-1 and alpha-2 domains. These are:
CC B*07:02; B*08:01; B*13:02; B*15:01; B*18:01; B*27:05; B*35:01; B*37:01;
CC B*38:01; B*40:01; B*44:02; B*45:01; B*51:01; B*54:01; B*57:01 and
CC B*73:01. Among these, B*07:02; B*15:01; B*18:01; B*37:01; B*51:01;
CC B*54:01; B*57:01 and B*73:01, were likely passed by introgression from
CC archaic to modern humans. Functional alleles of more recent origin
CC (non-core) were derived by recombination (PubMed:28650991). The
CC sequence shown is that of B*07:02. The sequences of core alleles and
CC common representative alleles of serologically distinct allele groups
CC are described as variants of B*07:02. Allelic variations of HLA-B
CC signal peptide regulate HLA-E recognition by KLRD1-KLRC1 and KLRD1-
CC KLRC2 receptors in viral infection and tumorigenesis by affecting its
CC processing and by changing the affinity of HLA-E-VL9 complex for KLRD1-
CC KLRC1 and KLRD1-KLRC2 receptors. {ECO:0000269|PubMed:28650991,
CC ECO:0000269|PubMed:37264229}.
CC -!- DISEASE: Stevens-Johnson syndrome (SJS) [MIM:608579]: A rare blistering
CC mucocutaneous disease that share clinical and histopathologic features
CC with toxic epidermal necrolysis. Both disorders are characterized by
CC high fever, malaise, and a rapidly developing blistering exanthema of
CC macules and target-like lesions accompanied by mucosal involvement.
CC Stevens-Johnson syndrome is a milder disease characterized by
CC destruction and detachment of the skin epithelium and mucous membranes
CC involving less than 10% of the body surface area. Ocular symptoms
CC include ulcerative conjunctivitis, keratitis, iritis, uveitis and
CC sometimes blindness. It can be caused by a severe adverse reaction to
CC particular types of medication, although Mycoplasma infections may
CC induce some cases. Note=Disease susceptibility is associated with
CC variants affecting the gene represented in this entry. Increased
CC susceptibility to Stevens-Johnson syndrome is conferred by allele
CC B*15:02. {ECO:0000269|PubMed:15057820}.
CC -!- DISEASE: Spondyloarthropathy 1 (SPDA1) [MIM:106300]: A chronic
CC rheumatic disease with multifactorial inheritance. It includes a
CC spectrum of related disorders comprising ankylosing spondylitis, a
CC subset of psoriatic arthritis, reactive arthritis (e.g. Reiter
CC syndrome), arthritis associated with inflammatory bowel disease and
CC undifferentiated spondyloarthropathy. These disorders may occur
CC simultaneously or sequentially in the same patient, probably
CC representing various phenotypic expressions of the same disease.
CC Ankylosing spondylitis is the form of rheumatoid arthritis affecting
CC the spine and is considered the prototype of seronegative
CC spondyloarthropathies. It produces pain and stiffness as a result of
CC inflammation of the sacroiliac, intervertebral, and costovertebral
CC joints. Note=Disease susceptibility is associated with variants
CC affecting the gene represented in this entry. A restricted number of
CC HLA-B*27 subtypes can be associated with ankylosing spondylitis and
CC other B*27-related diseases, and an elevated frequency of the B*27:02
CC allele in ankylosing spondylitis patients is identified. The allele
CC B*27:07 seems to have a protective role in some populations because it
CC was found only in the healthy controls. {ECO:0000269|PubMed:15603872}.
CC -!- DISEASE: Note=There is evidence that HLA-B*51 is associated with
CC susceptibility to Behcet disease (BD). However, it is not certain
CC whether HLA-B*51 itself or a closely linked gene is responsible for
CC susceptibility. The world distribution of HLA-B*51 in healthy people
CC corresponds to the global distribution of BD; in Southern hemisphere
CC countries (Africa, South Pacific, etc.) and in some parts of Europe,
CC the prevalence of HLA-B*51 in healthy people is low or null,
CC corresponding to a low prevalence of BD. The wide variation that exists
CC in the relative risk of HLA-B*51 would support other nongenetic risk
CC factors. {ECO:0000269|PubMed:23291587}.
CC -!- DISEASE: Note=The presence of allele B*57:01 is associated with
CC increased susceptibility to abacavir hypersensitivity [MIM:142830] in
CC HIV-1 patients. {ECO:0000269|PubMed:11888582}.
CC -!- DISEASE: Note=Allele group B*08 is associated with increased
CC susceptibility to rheumatoid arthritis, where affected individuals have
CC antibodies to cyclic citrullinated peptide (anti-CCP-positive
CC rheumatoid arthritis). {ECO:0000269|PubMed:22286218}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; U03698; AAA03719.1; -; mRNA.
DR EMBL; M32317; AAA36230.1; -; mRNA.
DR EMBL; M32320; AAA36233.1; -; mRNA.
DR EMBL; M32319; AAA36232.1; -; mRNA.
DR EMBL; M32318; AAA36231.1; -; mRNA.
DR EMBL; M77774; AAA03686.1; -; mRNA.
DR EMBL; M77778; AAA03687.1; -; mRNA.
DR EMBL; M77776; AAA03689.1; -; mRNA.
DR EMBL; X61710; CAA43879.1; -; mRNA.
DR EMBL; X61706; CAA43875.1; -; mRNA.
DR EMBL; X61708; CAA43877.1; -; mRNA.
DR EMBL; M24037; AAA02950.1; -; mRNA.
DR EMBL; M84380; AAA59629.1; -; mRNA.
DR EMBL; L09736; AAA36224.1; -; mRNA.
DR EMBL; D14343; BAA03277.1; -; mRNA.
DR EMBL; M83193; AAA58628.1; -; mRNA.
DR EMBL; L07743; AAA59621.1; -; mRNA.
DR EMBL; X77658; CAA54739.1; -; mRNA.
DR EMBL; U03859; AAA03601.1; -; mRNA.
DR EMBL; U04787; AAA53175.1; -; mRNA.
DR EMBL; L24373; AAA96733.1; -; mRNA.
DR EMBL; D50291; BAA08822.1; -; mRNA.
DR EMBL; L37880; AAC41941.1; -; mRNA.
DR EMBL; L36591; AAA73509.1; -; mRNA.
DR EMBL; U04243; AAA87396.1; -; mRNA.
DR EMBL; X90390; CAA62035.1; -; mRNA.
DR EMBL; U36492; AAB18369.1; -; mRNA.
DR EMBL; D50292; BAA08823.1; -; mRNA.
DR EMBL; AB008102; BAA22916.1; -; mRNA.
DR EMBL; M11799; AAA59628.1; -; Genomic_DNA.
DR EMBL; X03665; CAA27302.1; -; Genomic_DNA.
DR EMBL; X03666; CAA27302.1; JOINED; Genomic_DNA.
DR EMBL; M14013; AAA59643.1; -; Genomic_DNA.
DR EMBL; M19757; AAA52657.1; -; Genomic_DNA.
DR EMBL; M19756; AAA52664.1; -; Genomic_DNA.
DR EMBL; M28115; AAA59617.1; -; Genomic_DNA.
DR EMBL; M28109; AAA59617.1; JOINED; Genomic_DNA.
DR EMBL; M28110; AAA59617.1; JOINED; Genomic_DNA.
DR EMBL; M28111; AAA59617.1; JOINED; Genomic_DNA.
DR EMBL; M28112; AAA59617.1; JOINED; Genomic_DNA.
DR EMBL; M28113; AAA59617.1; JOINED; Genomic_DNA.
DR EMBL; M28114; AAA59617.1; JOINED; Genomic_DNA.
DR EMBL; L41087; AAA64513.1; -; Genomic_DNA.
DR EMBL; L41086; AAA64513.1; JOINED; Genomic_DNA.
DR EMBL; M24036; AAA52662.1; -; Genomic_DNA.
DR EMBL; M24041; AAA59660.1; -; Genomic_DNA.
DR EMBL; M24040; AAA59661.1; -; Genomic_DNA.
DR EMBL; M24035; AAA59666.1; -; Genomic_DNA.
DR EMBL; M24039; AAA59662.1; -; Genomic_DNA.
DR EMBL; M24034; AAA59667.1; -; Genomic_DNA.
DR EMBL; M24038; AAA59663.1; -; Genomic_DNA.
DR EMBL; M24033; AAA59665.1; -; mRNA.
DR EMBL; M58636; AAA36228.1; -; Genomic_DNA.
DR EMBL; M33573; AAA59644.1; -; Genomic_DNA.
DR EMBL; X55711; CAA39244.1; -; Genomic_DNA.
DR EMBL; M94053; AAA52659.1; -; Genomic_DNA.
DR EMBL; L41628; AAA65040.1; -; Genomic_DNA.
DR EMBL; L17005; AAC37548.1; -; mRNA.
DR EMBL; AJ292075; CAC33440.1; -; Genomic_DNA.
DR EMBL; AJ295294; CAC18876.1; -; Genomic_DNA.
DR EMBL; AJ310507; CAC34572.1; -; Genomic_DNA.
DR EMBL; AJ309193; CAC38392.1; -; Genomic_DNA.
DR EMBL; AJ309194; CAC38393.1; -; Genomic_DNA.
DR EMBL; AJ458992; CAD30340.1; -; Genomic_DNA.
DR EMBL; AJ310508; CAC34573.1; -; Genomic_DNA.
DR EMBL; AJ308398; CAC33087.2; -; Genomic_DNA.
DR EMBL; AJ309139; CAC38066.1; -; Genomic_DNA.
DR EMBL; AJ310509; CAC34574.1; -; Genomic_DNA.
DR EMBL; HM543719; ADU18071.1; -; Genomic_DNA.
DR EMBL; HM543720; ADU18072.1; -; Genomic_DNA.
DR EMBL; JF974053; AEN79482.1; -; Genomic_DNA.
DR EMBL; U11267; AAA19927.1; -; mRNA.
DR EMBL; U11261; AAA19921.1; -; mRNA.
DR EMBL; D50300; BAA08829.1; -; mRNA.
DR EMBL; U29057; AAA91229.1; -; mRNA.
DR EMBL; U38800; AAC99997.1; -; mRNA.
DR EMBL; U40498; AAD00010.1; -; mRNA.
DR EMBL; AJ309936; CAC33891.1; -; Genomic_DNA.
DR EMBL; AJ309047; CAC35468.1; -; Genomic_DNA.
DR EMBL; AJ310358; CAC38763.1; -; Genomic_DNA.
DR EMBL; AJ309192; CAC38391.1; -; Genomic_DNA.
DR EMBL; MG525292; AUM84865.1; -; Genomic_DNA.
DR EMBL; AY007140; AAG02001.1; -; mRNA.
DR EMBL; BA000025; BAB63309.1; -; Genomic_DNA.
DR EMBL; BC007243; AAH07243.1; -; mRNA.
DR EMBL; AK313911; BAG36634.1; -; mRNA.
DR EMBL; CR759828; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR CCDS; CCDS34394.1; -.
DR RefSeq; NP_005505.2; NM_005514.7.
DR PDB; 1A1M; X-ray; 2.30 A; A=25-300.
DR PDB; 1A1N; X-ray; 2.00 A; A=25-300.
DR PDB; 1A1O; X-ray; 2.30 A; A=25-300.
DR PDB; 1A9B; X-ray; 3.20 A; A/D=25-301.
DR PDB; 1A9E; X-ray; 2.50 A; A=25-301.
DR PDB; 1AGB; X-ray; 2.20 A; A=25-300.
DR PDB; 1AGC; X-ray; 2.10 A; A=25-300.
DR PDB; 1AGD; X-ray; 2.05 A; A=25-300.
DR PDB; 1AGE; X-ray; 2.30 A; A=25-300.
DR PDB; 1AGF; X-ray; 2.20 A; A=25-300.
DR PDB; 1CG9; X-ray; 2.70 A; A=25-301.
DR PDB; 1E27; X-ray; 2.20 A; A=25-300.
DR PDB; 1E28; X-ray; 3.00 A; A=25-300.
DR PDB; 1HSA; X-ray; 2.10 A; A/D=25-300.
DR PDB; 1JGD; X-ray; 1.90 A; A=25-300.
DR PDB; 1JGE; X-ray; 2.10 A; A=25-300.
DR PDB; 1K5N; X-ray; 1.09 A; A=25-300.
DR PDB; 1M05; X-ray; 1.90 A; A/C=25-301.
DR PDB; 1M6O; X-ray; 1.60 A; A=25-300.
DR PDB; 1MI5; X-ray; 2.50 A; A=25-301.
DR PDB; 1N2R; X-ray; 1.70 A; A=25-300.
DR PDB; 1OF2; X-ray; 2.20 A; A=25-300.
DR PDB; 1OGT; X-ray; 1.47 A; A=25-300.
DR PDB; 1SYS; X-ray; 2.40 A; A=25-300.
DR PDB; 1SYV; X-ray; 1.70 A; A=25-300.
DR PDB; 1UXS; X-ray; 1.55 A; A=25-300.
DR PDB; 1UXW; X-ray; 1.71 A; A=25-300.
DR PDB; 1W0V; X-ray; 2.27 A; A=25-300.
DR PDB; 1W0W; X-ray; 2.11 A; A=25-300.
DR PDB; 1XH3; X-ray; 1.48 A; A=25-300.
DR PDB; 1XR8; X-ray; 2.30 A; A=25-300.
DR PDB; 1XR9; X-ray; 1.79 A; A=25-300.
DR PDB; 1ZHK; X-ray; 1.60 A; A=25-300.
DR PDB; 1ZHL; X-ray; 1.50 A; A=25-300.
DR PDB; 1ZSD; X-ray; 1.70 A; A=25-300.
DR PDB; 2A83; X-ray; 1.40 A; A=25-300.
DR PDB; 2AK4; X-ray; 2.50 A; A/F/K/Q=25-300.
DR PDB; 2AXF; X-ray; 1.80 A; A=25-300.
DR PDB; 2AXG; X-ray; 2.00 A; A=25-300.
DR PDB; 2BSR; X-ray; 2.30 A; A=25-300.
DR PDB; 2BSS; X-ray; 2.00 A; A=25-300.
DR PDB; 2BST; X-ray; 2.10 A; A=25-300.
DR PDB; 2BVO; X-ray; 1.65 A; A=25-300.
DR PDB; 2BVP; X-ray; 1.35 A; A=25-300.
DR PDB; 2BVQ; X-ray; 2.00 A; A=25-300.
DR PDB; 2H6P; X-ray; 1.90 A; A=25-300.
DR PDB; 2HJL; X-ray; 1.50 A; A=25-298.
DR PDB; 2NW3; X-ray; 1.70 A; A=25-300.
DR PDB; 2NX5; X-ray; 2.70 A; A/F/K/Q=25-300.
DR PDB; 2RFX; X-ray; 2.50 A; A=25-299.
DR PDB; 2YPK; X-ray; 1.95 A; A=25-298.
DR PDB; 2YPL; X-ray; 2.40 A; A=25-298.
DR PDB; 3B3I; X-ray; 1.86 A; A=25-300.
DR PDB; 3B6S; X-ray; 1.80 A; A=25-300.
DR PDB; 3BP4; X-ray; 1.85 A; A=25-300.
DR PDB; 3BP7; X-ray; 1.80 A; A=25-300.
DR PDB; 3BW9; X-ray; 1.75 A; A=25-300.
DR PDB; 3BWA; X-ray; 1.30 A; A=25-300.
DR PDB; 3C9N; X-ray; 1.87 A; A=25-300.
DR PDB; 3CZF; X-ray; 1.20 A; A=25-300.
DR PDB; 3D18; X-ray; 1.74 A; A=25-300.
DR PDB; 3DTX; X-ray; 2.10 A; A=25-300.
DR PDB; 3DX6; X-ray; 1.70 A; A=25-300.
DR PDB; 3DX7; X-ray; 1.60 A; A=25-300.
DR PDB; 3DX8; X-ray; 2.10 A; A=25-300.
DR PDB; 3DXA; X-ray; 3.50 A; A/F/K=25-300.
DR PDB; 3FFC; X-ray; 2.80 A; A/F=25-301.
DR PDB; 3HCV; X-ray; 1.95 A; A=25-300.
DR PDB; 3KPL; X-ray; 1.96 A; A=25-300.
DR PDB; 3KPM; X-ray; 1.60 A; A=25-300.
DR PDB; 3KPN; X-ray; 2.00 A; A=25-300.
DR PDB; 3KPO; X-ray; 2.30 A; A=25-300.
DR PDB; 3KPP; X-ray; 1.90 A; A=25-300.
DR PDB; 3KPQ; X-ray; 1.84 A; A=25-300.
DR PDB; 3KPR; X-ray; 2.60 A; A/F=25-300.
DR PDB; 3KPS; X-ray; 2.70 A; A=25-300.
DR PDB; 3KWW; X-ray; 2.18 A; A=25-300.
DR PDB; 3KXF; X-ray; 3.10 A; A/C/I/K=25-300.
DR PDB; 3L3D; X-ray; 1.80 A; A=25-300.
DR PDB; 3L3G; X-ray; 2.10 A; A=25-300.
DR PDB; 3L3I; X-ray; 1.70 A; A=25-300.
DR PDB; 3L3J; X-ray; 2.40 A; A=25-300.
DR PDB; 3L3K; X-ray; 2.60 A; A=25-300.
DR PDB; 3LKN; X-ray; 2.00 A; A=25-300.
DR PDB; 3LKO; X-ray; 1.80 A; A=25-300.
DR PDB; 3LKP; X-ray; 1.80 A; A=25-300.
DR PDB; 3LKQ; X-ray; 1.80 A; A=25-300.
DR PDB; 3LKR; X-ray; 2.00 A; A=25-300.
DR PDB; 3LKS; X-ray; 1.90 A; A=25-300.
DR PDB; 3LN4; X-ray; 1.30 A; A=25-298.
DR PDB; 3LN5; X-ray; 1.90 A; A=25-298.
DR PDB; 3LV3; X-ray; 1.94 A; A=25-300.
DR PDB; 3MV7; X-ray; 2.00 A; A=25-300.
DR PDB; 3MV8; X-ray; 2.10 A; A=25-300.
DR PDB; 3MV9; X-ray; 2.70 A; A=25-300.
DR PDB; 3SJV; X-ray; 3.10 A; A/F/K/P=25-301.
DR PDB; 3SKM; X-ray; 1.80 A; A=25-300.
DR PDB; 3SKO; X-ray; 1.60 A; A=25-301.
DR PDB; 3SPV; X-ray; 1.30 A; A=25-300.
DR PDB; 3UPR; X-ray; 2.00 A; A/C=25-300.
DR PDB; 3VCL; X-ray; 1.70 A; A=25-299.
DR PDB; 3VFS; X-ray; 1.85 A; A=25-300.
DR PDB; 3VFT; X-ray; 1.95 A; A=25-300.
DR PDB; 3VFU; X-ray; 1.65 A; A=25-300.
DR PDB; 3VFV; X-ray; 1.55 A; A=25-300.
DR PDB; 3VFW; X-ray; 2.30 A; A=25-300.
DR PDB; 3VH8; X-ray; 1.80 A; A/D=25-299.
DR PDB; 3VRI; X-ray; 1.60 A; A=25-300.
DR PDB; 3VRJ; X-ray; 1.90 A; A=25-300.
DR PDB; 3W39; X-ray; 3.10 A; A/D=25-300.
DR PDB; 3WUW; X-ray; 2.00 A; A=25-299.
DR PDB; 3X11; X-ray; 2.15 A; A=25-300.
DR PDB; 3X12; X-ray; 1.80 A; A=25-300.
DR PDB; 3X13; X-ray; 1.80 A; A=25-300.
DR PDB; 3X14; X-ray; 2.00 A; A=25-300.
DR PDB; 4G8G; X-ray; 2.40 A; A=25-300.
DR PDB; 4G8I; X-ray; 1.60 A; A=25-300.
DR PDB; 4G9D; X-ray; 1.60 A; A=25-300.
DR PDB; 4G9F; X-ray; 1.90 A; A=25-300.
DR PDB; 4JQV; X-ray; 1.50 A; A=25-302.
DR PDB; 4JQX; X-ray; 1.90 A; A=25-302.
DR PDB; 4LCY; X-ray; 1.60 A; A/F=25-298.
DR PDB; 4LNR; X-ray; 2.00 A; A=25-300.
DR PDB; 4MJI; X-ray; 2.99 A; A/F=25-300.
DR PDB; 4O2C; X-ray; 1.80 A; A=25-298.
DR PDB; 4O2E; X-ray; 1.98 A; A/D=25-298.
DR PDB; 4O2F; X-ray; 1.90 A; A/D=25-298.
DR PDB; 4PR5; X-ray; 1.80 A; A=25-300.
DR PDB; 4PRN; X-ray; 1.65 A; A=25-300.
DR PDB; 4QRP; X-ray; 2.90 A; A/F=25-300.
DR PDB; 4QRQ; X-ray; 1.70 A; A=25-300.
DR PDB; 4QRR; X-ray; 3.00 A; A=25-300.
DR PDB; 4QRS; X-ray; 1.40 A; A=25-300.
DR PDB; 4QRT; X-ray; 1.40 A; A=25-300.
DR PDB; 4QRU; X-ray; 1.60 A; A=25-300.
DR PDB; 4U1H; X-ray; 1.59 A; A=25-300.
DR PDB; 4U1I; X-ray; 1.92 A; A=25-301.
DR PDB; 4U1J; X-ray; 1.38 A; A=25-301.
DR PDB; 4U1K; X-ray; 2.09 A; A/D=25-300.
DR PDB; 4U1L; X-ray; 2.06 A; A/D=25-300.
DR PDB; 4U1M; X-ray; 1.18 A; A=25-301.
DR PDB; 4U1N; X-ray; 1.77 A; A=25-301.
DR PDB; 4U1S; X-ray; 1.76 A; A=25-301.
DR PDB; 4XXC; X-ray; 1.43 A; A=25-303.
DR PDB; 5B38; X-ray; 2.30 A; A=25-300.
DR PDB; 5B39; X-ray; 2.50 A; A=25-300.
DR PDB; 5DEF; X-ray; 1.60 A; A=25-300.
DR PDB; 5DEG; X-ray; 1.83 A; A=25-300.
DR PDB; 5EO0; X-ray; 1.70 A; A=25-299.
DR PDB; 5EO1; X-ray; 1.85 A; A=25-299.
DR PDB; 5IB1; X-ray; 1.91 A; A=25-300.
DR PDB; 5IB2; X-ray; 1.44 A; A=25-300.
DR PDB; 5IB3; X-ray; 1.91 A; A=25-300.
DR PDB; 5IB4; X-ray; 1.95 A; A=25-300.
DR PDB; 5IB5; X-ray; 2.49 A; A/D=25-300.
DR PDB; 5IEH; X-ray; 1.50 A; A=25-300.
DR PDB; 5IEK; X-ray; 1.80 A; A=25-300.
DR PDB; 5IM7; X-ray; 2.50 A; A/C=25-300.
DR PDB; 5INC; X-ray; 2.88 A; A/C=25-300.
DR PDB; 5IND; X-ray; 2.13 A; A/C=25-300.
DR PDB; 5T6W; X-ray; 1.90 A; A=25-300.
DR PDB; 5T6X; X-ray; 1.69 A; A=25-300.
DR PDB; 5T6Y; X-ray; 1.76 A; A=25-300.
DR PDB; 5T6Z; X-ray; 2.00 A; A=25-300.
DR PDB; 5T70; X-ray; 2.10 A; A=25-300.
DR PDB; 5TXS; X-ray; 1.70 A; A=25-304.
DR PDB; 5U98; X-ray; 2.00 A; A/D=25-300.
DR PDB; 5V5L; X-ray; 2.00 A; A/C=25-300.
DR PDB; 5V5M; X-ray; 2.88 A; A/C=25-300.
DR PDB; 5VUD; X-ray; 2.00 A; A=25-300.
DR PDB; 5VUE; X-ray; 1.80 A; A=25-300.
DR PDB; 5VUF; X-ray; 1.90 A; A=25-300.
DR PDB; 5VWD; X-ray; 1.80 A; A=25-300.
DR PDB; 5VWF; X-ray; 1.80 A; A=25-300.
DR PDB; 5VWH; X-ray; 1.65 A; A=25-300.
DR PDB; 5VWJ; X-ray; 2.00 A; A=25-300.
DR PDB; 5VZ5; X-ray; 2.59 A; A=25-304.
DR PDB; 5WMN; X-ray; 1.82 A; A/C=25-300.
DR PDB; 5WMO; X-ray; 1.62 A; A=25-300.
DR PDB; 5WMP; X-ray; 1.60 A; A=25-300.
DR PDB; 5WMQ; X-ray; 1.40 A; A=25-300.
DR PDB; 5WMR; X-ray; 1.58 A; A=25-300.
DR PDB; 5XOS; X-ray; 1.70 A; A=25-300.
DR PDB; 5XOT; X-ray; 2.79 A; A=25-300.
DR PDB; 6AT5; X-ray; 1.50 A; A=1-362.
DR PDB; 6AVF; X-ray; 2.03 A; H=1-362.
DR PDB; 6AVG; X-ray; 2.60 A; F/G=1-362.
DR PDB; 6BJ2; X-ray; 3.35 A; A=25-300.
DR PDB; 6BJ3; X-ray; 1.90 A; A=25-300.
DR PDB; 6BJ8; X-ray; 1.75 A; A=25-300.
DR PDB; 6BXP; X-ray; 1.45 A; A=25-300.
DR PDB; 6BXQ; X-ray; 1.58 A; B=25-300.
DR PDB; 6D29; X-ray; 1.88 A; A=25-300.
DR PDB; 6D2B; X-ray; 2.04 A; A=25-300.
DR PDB; 6D2R; X-ray; 1.83 A; A=25-300.
DR PDB; 6D2T; X-ray; 1.90 A; A=25-300.
DR PDB; 6MT3; X-ray; 1.21 A; A=25-300.
DR PDB; 6MT4; X-ray; 1.55 A; A=25-300.
DR PDB; 6MT5; X-ray; 1.55 A; A=25-300.
DR PDB; 6MT6; X-ray; 1.31 A; A=25-300.
DR PDB; 6MTL; X-ray; 1.35 A; A=25-300.
DR PDB; 6MTM; X-ray; 3.00 A; A=25-300.
DR PDB; 6P23; X-ray; 1.59 A; A=25-300.
DR PDB; 6P27; X-ray; 1.59 A; A=25-300.
DR PDB; 6P2C; X-ray; 1.40 A; A=25-300.
DR PDB; 6P2F; X-ray; 1.48 A; A=25-300.
DR PDB; 6P2S; X-ray; 1.65 A; A=25-300.
DR PDB; 6PYJ; X-ray; 1.44 A; A=25-300.
DR PDB; 6PYL; X-ray; 1.52 A; A=25-300.
DR PDB; 6PYV; X-ray; 1.45 A; A=25-300.
DR PDB; 6PYW; X-ray; 1.38 A; A=25-300.
DR PDB; 6PZ5; X-ray; 1.53 A; A=25-300.
DR PDB; 6UJ7; X-ray; 1.90 A; A/D=25-304.
DR PDB; 6UJ8; X-ray; 2.25 A; A/D=25-304.
DR PDB; 6UJ9; X-ray; 2.90 A; A=25-304.
DR PDB; 6VMX; X-ray; 3.10 A; A/F=25-300.
DR PDB; 7LFZ; X-ray; 1.90 A; A=25-299.
DR PDB; 7LG0; X-ray; 2.30 A; A=25-299.
DR PDB; 7LGD; X-ray; 2.88 A; A/C=25-302.
DR PDB; 7LGT; X-ray; 1.97 A; A/C=25-302.
DR PDB; 7RZD; X-ray; 1.82 A; A=25-299.
DR PDB; 7RZJ; X-ray; 1.80 A; A=25-299.
DR PDB; 7S79; X-ray; 1.53 A; A=25-299.
DR PDB; 7S7D; X-ray; 1.56 A; A=25-299.
DR PDB; 7S7E; X-ray; 2.04 A; A=25-299.
DR PDB; 7S7F; X-ray; 1.88 A; A=25-299.
DR PDB; 7S8A; X-ray; 2.10 A; A=25-299.
DR PDB; 7S8E; X-ray; 1.60 A; A=25-299.
DR PDB; 7S8F; X-ray; 1.80 A; A=25-299.
DR PDBsum; 1A1M; -.
DR PDBsum; 1A1N; -.
DR PDBsum; 1A1O; -.
DR PDBsum; 1A9B; -.
DR PDBsum; 1A9E; -.
DR PDBsum; 1AGB; -.
DR PDBsum; 1AGC; -.
DR PDBsum; 1AGD; -.
DR PDBsum; 1AGE; -.
DR PDBsum; 1AGF; -.
DR PDBsum; 1CG9; -.
DR PDBsum; 1E27; -.
DR PDBsum; 1E28; -.
DR PDBsum; 1HSA; -.
DR PDBsum; 1JGD; -.
DR PDBsum; 1JGE; -.
DR PDBsum; 1K5N; -.
DR PDBsum; 1M05; -.
DR PDBsum; 1M6O; -.
DR PDBsum; 1MI5; -.
DR PDBsum; 1N2R; -.
DR PDBsum; 1OF2; -.
DR PDBsum; 1OGT; -.
DR PDBsum; 1SYS; -.
DR PDBsum; 1SYV; -.
DR PDBsum; 1UXS; -.
DR PDBsum; 1UXW; -.
DR PDBsum; 1W0V; -.
DR PDBsum; 1W0W; -.
DR PDBsum; 1XH3; -.
DR PDBsum; 1XR8; -.
DR PDBsum; 1XR9; -.
DR PDBsum; 1ZHK; -.
DR PDBsum; 1ZHL; -.
DR PDBsum; 1ZSD; -.
DR PDBsum; 2A83; -.
DR PDBsum; 2AK4; -.
DR PDBsum; 2AXF; -.
DR PDBsum; 2AXG; -.
DR PDBsum; 2BSR; -.
DR PDBsum; 2BSS; -.
DR PDBsum; 2BST; -.
DR PDBsum; 2BVO; -.
DR PDBsum; 2BVP; -.
DR PDBsum; 2BVQ; -.
DR PDBsum; 2H6P; -.
DR PDBsum; 2HJL; -.
DR PDBsum; 2NW3; -.
DR PDBsum; 2NX5; -.
DR PDBsum; 2RFX; -.
DR PDBsum; 2YPK; -.
DR PDBsum; 2YPL; -.
DR PDBsum; 3B3I; -.
DR PDBsum; 3B6S; -.
DR PDBsum; 3BP4; -.
DR PDBsum; 3BP7; -.
DR PDBsum; 3BW9; -.
DR PDBsum; 3BWA; -.
DR PDBsum; 3C9N; -.
DR PDBsum; 3CZF; -.
DR PDBsum; 3D18; -.
DR PDBsum; 3DTX; -.
DR PDBsum; 3DX6; -.
DR PDBsum; 3DX7; -.
DR PDBsum; 3DX8; -.
DR PDBsum; 3DXA; -.
DR PDBsum; 3FFC; -.
DR PDBsum; 3HCV; -.
DR PDBsum; 3KPL; -.
DR PDBsum; 3KPM; -.
DR PDBsum; 3KPN; -.
DR PDBsum; 3KPO; -.
DR PDBsum; 3KPP; -.
DR PDBsum; 3KPQ; -.
DR PDBsum; 3KPR; -.
DR PDBsum; 3KPS; -.
DR PDBsum; 3KWW; -.
DR PDBsum; 3KXF; -.
DR PDBsum; 3L3D; -.
DR PDBsum; 3L3G; -.
DR PDBsum; 3L3I; -.
DR PDBsum; 3L3J; -.
DR PDBsum; 3L3K; -.
DR PDBsum; 3LKN; -.
DR PDBsum; 3LKO; -.
DR PDBsum; 3LKP; -.
DR PDBsum; 3LKQ; -.
DR PDBsum; 3LKR; -.
DR PDBsum; 3LKS; -.
DR PDBsum; 3LN4; -.
DR PDBsum; 3LN5; -.
DR PDBsum; 3LV3; -.
DR PDBsum; 3MV7; -.
DR PDBsum; 3MV8; -.
DR PDBsum; 3MV9; -.
DR PDBsum; 3SJV; -.
DR PDBsum; 3SKM; -.
DR PDBsum; 3SKO; -.
DR PDBsum; 3SPV; -.
DR PDBsum; 3UPR; -.
DR PDBsum; 3VCL; -.
DR PDBsum; 3VFS; -.
DR PDBsum; 3VFT; -.
DR PDBsum; 3VFU; -.
DR PDBsum; 3VFV; -.
DR PDBsum; 3VFW; -.
DR PDBsum; 3VH8; -.
DR PDBsum; 3VRI; -.
DR PDBsum; 3VRJ; -.
DR PDBsum; 3W39; -.
DR PDBsum; 3WUW; -.
DR PDBsum; 3X11; -.
DR PDBsum; 3X12; -.
DR PDBsum; 3X13; -.
DR PDBsum; 3X14; -.
DR PDBsum; 4G8G; -.
DR PDBsum; 4G8I; -.
DR PDBsum; 4G9D; -.
DR PDBsum; 4G9F; -.
DR PDBsum; 4JQV; -.
DR PDBsum; 4JQX; -.
DR PDBsum; 4LCY; -.
DR PDBsum; 4LNR; -.
DR PDBsum; 4MJI; -.
DR PDBsum; 4O2C; -.
DR PDBsum; 4O2E; -.
DR PDBsum; 4O2F; -.
DR PDBsum; 4PR5; -.
DR PDBsum; 4PRN; -.
DR PDBsum; 4QRP; -.
DR PDBsum; 4QRQ; -.
DR PDBsum; 4QRR; -.
DR PDBsum; 4QRS; -.
DR PDBsum; 4QRT; -.
DR PDBsum; 4QRU; -.
DR PDBsum; 4U1H; -.
DR PDBsum; 4U1I; -.
DR PDBsum; 4U1J; -.
DR PDBsum; 4U1K; -.
DR PDBsum; 4U1L; -.
DR PDBsum; 4U1M; -.
DR PDBsum; 4U1N; -.
DR PDBsum; 4U1S; -.
DR PDBsum; 4XXC; -.
DR PDBsum; 5B38; -.
DR PDBsum; 5B39; -.
DR PDBsum; 5DEF; -.
DR PDBsum; 5DEG; -.
DR PDBsum; 5EO0; -.
DR PDBsum; 5EO1; -.
DR PDBsum; 5IB1; -.
DR PDBsum; 5IB2; -.
DR PDBsum; 5IB3; -.
DR PDBsum; 5IB4; -.
DR PDBsum; 5IB5; -.
DR PDBsum; 5IEH; -.
DR PDBsum; 5IEK; -.
DR PDBsum; 5IM7; -.
DR PDBsum; 5INC; -.
DR PDBsum; 5IND; -.
DR PDBsum; 5T6W; -.
DR PDBsum; 5T6X; -.
DR PDBsum; 5T6Y; -.
DR PDBsum; 5T6Z; -.
DR PDBsum; 5T70; -.
DR PDBsum; 5TXS; -.
DR PDBsum; 5U98; -.
DR PDBsum; 5V5L; -.
DR PDBsum; 5V5M; -.
DR PDBsum; 5VUD; -.
DR PDBsum; 5VUE; -.
DR PDBsum; 5VUF; -.
DR PDBsum; 5VWD; -.
DR PDBsum; 5VWF; -.
DR PDBsum; 5VWH; -.
DR PDBsum; 5VWJ; -.
DR PDBsum; 5VZ5; -.
DR PDBsum; 5WMN; -.
DR PDBsum; 5WMO; -.
DR PDBsum; 5WMP; -.
DR PDBsum; 5WMQ; -.
DR PDBsum; 5WMR; -.
DR PDBsum; 5XOS; -.
DR PDBsum; 5XOT; -.
DR PDBsum; 6AT5; -.
DR PDBsum; 6AVF; -.
DR PDBsum; 6AVG; -.
DR PDBsum; 6BJ2; -.
DR PDBsum; 6BJ3; -.
DR PDBsum; 6BJ8; -.
DR PDBsum; 6BXP; -.
DR PDBsum; 6BXQ; -.
DR PDBsum; 6D29; -.
DR PDBsum; 6D2B; -.
DR PDBsum; 6D2R; -.
DR PDBsum; 6D2T; -.
DR PDBsum; 6MT3; -.
DR PDBsum; 6MT4; -.
DR PDBsum; 6MT5; -.
DR PDBsum; 6MT6; -.
DR PDBsum; 6MTL; -.
DR PDBsum; 6MTM; -.
DR PDBsum; 6P23; -.
DR PDBsum; 6P27; -.
DR PDBsum; 6P2C; -.
DR PDBsum; 6P2F; -.
DR PDBsum; 6P2S; -.
DR PDBsum; 6PYJ; -.
DR PDBsum; 6PYL; -.
DR PDBsum; 6PYV; -.
DR PDBsum; 6PYW; -.
DR PDBsum; 6PZ5; -.
DR PDBsum; 6UJ7; -.
DR PDBsum; 6UJ8; -.
DR PDBsum; 6UJ9; -.
DR PDBsum; 6VMX; -.
DR PDBsum; 7LFZ; -.
DR PDBsum; 7LG0; -.
DR PDBsum; 7LGD; -.
DR PDBsum; 7LGT; -.
DR PDBsum; 7RZD; -.
DR PDBsum; 7RZJ; -.
DR PDBsum; 7S79; -.
DR PDBsum; 7S7D; -.
DR PDBsum; 7S7E; -.
DR PDBsum; 7S7F; -.
DR PDBsum; 7S8A; -.
DR PDBsum; 7S8E; -.
DR PDBsum; 7S8F; -.
DR AlphaFoldDB; P01889; -.
DR SMR; P01889; -.
DR BioGRID; 109351; 293.
DR IntAct; P01889; 98.
DR MINT; P01889; -.
DR STRING; 9606.ENSP00000399168; -.
DR DrugBank; DB01048; Abacavir.
DR DrugBank; DB11294; Coccidioides immitis spherule.
DR DrugBank; DB04464; N-Formylmethionine.
DR TCDB; 9.A.75.1.3; the mhc ii receptor (mhc2r) family.
DR GlyConnect; 1331; 1 N-Linked glycan (1 site).
DR GlyConnect; 1332; 8 N-Linked glycans (1 site).
DR GlyConnect; 1333; 8 N-Linked glycans (1 site).
DR GlyConnect; 1334; 5 N-Linked glycans (1 site).
DR GlyConnect; 1335; 2 N-Linked glycans (1 site).
DR GlyConnect; 1336; 2 N-Linked glycans (1 site).
DR GlyConnect; 1337; 8 N-Linked glycans (1 site).
DR GlyConnect; 1338; 2 N-Linked glycans (1 site).
DR GlyConnect; 1339; 2 N-Linked glycans (1 site).
DR GlyConnect; 1340; 3 N-Linked glycans (1 site).
DR GlyConnect; 1341; 8 N-Linked glycans (1 site).
DR GlyConnect; 1342; 2 N-Linked glycans (1 site).
DR GlyConnect; 1343; 2 N-Linked glycans (1 site).
DR GlyConnect; 1344; 3 N-Linked glycans (1 site).
DR GlyConnect; 1345; 1 N-Linked glycan (1 site).
DR GlyConnect; 1346; 3 N-Linked glycans (1 site).
DR GlyConnect; 1347; 8 N-Linked glycans (1 site).
DR GlyConnect; 1348; 2 N-Linked glycans (1 site).
DR GlyConnect; 1349; 2 N-Linked glycans (1 site).
DR GlyConnect; 1350; 8 N-Linked glycans (1 site).
DR GlyConnect; 1351; 2 N-Linked glycans (1 site).
DR GlyCosmos; P01889; 2 sites, 2 glycans.
DR GlyGen; P01889; 3 sites, 1 N-linked glycan (1 site), 2 O-linked glycans (2 sites).
DR iPTMnet; P01889; -.
DR PhosphoSitePlus; P01889; -.
DR SwissPalm; P01889; -.
DR BioMuta; HLA-B; -.
DR DMDM; 122160; -.
DR EPD; P01889; -.
DR jPOST; P01889; -.
DR MassIVE; P01889; -.
DR MaxQB; P01889; -.
DR PaxDb; 9606-ENSP00000399168; -.
DR PeptideAtlas; P01889; -.
DR ProteomicsDB; 51504; -.
DR ProteomicsDB; 51628; -.
DR ProteomicsDB; 52598; -.
DR ProteomicsDB; 53565; -.
DR ProteomicsDB; 53566; -.
DR ProteomicsDB; 53567; -.
DR ProteomicsDB; 54677; -.
DR ProteomicsDB; 54678; -.
DR ProteomicsDB; 54679; -.
DR ProteomicsDB; 54680; -.
DR ProteomicsDB; 54681; -.
DR ProteomicsDB; 54682; -.
DR ProteomicsDB; 54683; -.
DR ProteomicsDB; 54684; -.
DR ProteomicsDB; 54685; -.
DR ProteomicsDB; 54686; -.
DR ProteomicsDB; 54687; -.
DR ProteomicsDB; 54688; -.
DR ProteomicsDB; 54689; -.
DR ProteomicsDB; 54690; -.
DR ProteomicsDB; 54691; -.
DR ProteomicsDB; 54692; -.
DR ProteomicsDB; 54693; -.
DR ProteomicsDB; 54694; -.
DR ProteomicsDB; 54695; -.
DR ProteomicsDB; 54696; -.
DR ProteomicsDB; 54697; -.
DR ProteomicsDB; 54732; -.
DR ProteomicsDB; 58284; -.
DR ProteomicsDB; 61272; -.
DR ProteomicsDB; 61273; -.
DR ProteomicsDB; 61276; -.
DR ProteomicsDB; 61584; -.
DR ProteomicsDB; 61586; -.
DR ProteomicsDB; 75730; -.
DR Pumba; P01889; -.
DR Antibodypedia; 26900; 808 antibodies from 35 providers.
DR CPTC; P01889; 1 antibody.
DR DNASU; 3106; -.
DR Ensembl; ENST00000412585.7; ENSP00000399168.2; ENSG00000234745.14.
DR Ensembl; ENST00000696559.1; ENSP00000512717.1; ENSG00000234745.14.
DR Ensembl; ENST00000696560.1; ENSP00000512718.1; ENSG00000234745.14.
DR Ensembl; ENST00000696561.1; ENSP00000512719.1; ENSG00000234745.14.
DR Ensembl; ENST00000696562.1; ENSP00000512720.1; ENSG00000234745.14.
DR GeneID; 3106; -.
DR KEGG; hsa:3106; -.
DR MANE-Select; ENST00000412585.7; ENSP00000399168.2; NM_005514.8; NP_005505.2.
DR UCSC; uc011fcq.2; human.
DR UCSC; uc011hpp.3; human.
DR UCSC; uc011jij.3; human.
DR AGR; HGNC:4932; -.
DR CTD; 3106; -.
DR DisGeNET; 3106; -.
DR GeneCards; HLA-B; -.
DR HGNC; HGNC:4932; HLA-B.
DR HPA; ENSG00000234745; Tissue enhanced (lymphoid).
DR MalaCards; HLA-B; -.
DR MIM; 106300; phenotype.
DR MIM; 608579; phenotype.
DR neXtProt; NX_P01889; -.
DR OpenTargets; ENSG00000234745; -.
DR Orphanet; 117; Behcet disease.
DR Orphanet; 397; Giant cell arteritis.
DR Orphanet; 825; NON RARE IN EUROPE: Ankylosing spondylitis.
DR Orphanet; 275798; Pulmonary arterial hypertension associated with connective tissue disease.
DR Orphanet; 29207; Reactive arthritis.
DR Orphanet; 36426; Stevens-Johnson syndrome.
DR Orphanet; 3287; Takayasu arteritis.
DR PharmGKB; PA35056; -.
DR VEuPathDB; HostDB:ENSG00000234745; -.
DR eggNOG; ENOG502RQEK; Eukaryota.
DR GeneTree; ENSGT00980000198488; -.
DR HOGENOM; CLU_047501_1_1_1; -.
DR InParanoid; P01889; -.
DR OMA; KNERWIA; -.
DR OrthoDB; 3840485at2759; -.
DR PhylomeDB; P01889; -.
DR TreeFam; TF336617; -.
DR PathwayCommons; P01889; -.
DR Reactome; R-HSA-1236974; ER-Phagosome pathway.
DR Reactome; R-HSA-1236977; Endosomal/Vacuolar pathway.
DR Reactome; R-HSA-198933; Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell.
DR Reactome; R-HSA-2172127; DAP12 interactions.
DR Reactome; R-HSA-6798695; Neutrophil degranulation.
DR Reactome; R-HSA-877300; Interferon gamma signaling.
DR Reactome; R-HSA-909733; Interferon alpha/beta signaling.
DR Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses.
DR Reactome; R-HSA-983170; Antigen Presentation: Folding, assembly and peptide loading of class I MHC.
DR SignaLink; P01889; -.
DR SIGNOR; P01889; -.
DR BioGRID-ORCS; 3106; 25 hits in 1092 CRISPR screens.
DR ChiTaRS; HLA-B; human.
DR GeneWiki; HLA-B; -.
DR GenomeRNAi; 3106; -.
DR Pharos; P01889; Tbio.
DR PRO; PR:P01889; -.
DR Proteomes; UP000005640; Chromosome 6.
DR Bgee; ENSG00000234745; Expressed in blood and 101 other cell types or tissues.
DR ExpressionAtlas; P01889; baseline and differential.
DR GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR GO; GO:0031901; C:early endosome membrane; TAS:Reactome.
DR GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR GO; GO:0012507; C:ER to Golgi transport vesicle membrane; TAS:Reactome.
DR GO; GO:0009897; C:external side of plasma membrane; IBA:GO_Central.
DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR GO; GO:0005615; C:extracellular space; IBA:GO_Central.
DR GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR GO; GO:0098553; C:lumenal side of endoplasmic reticulum membrane; TAS:Reactome.
DR GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR GO; GO:0042612; C:MHC class I protein complex; IDA:UniProtKB.
DR GO; GO:0030670; C:phagocytic vesicle membrane; TAS:Reactome.
DR GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR GO; GO:0055038; C:recycling endosome membrane; TAS:Reactome.
DR GO; GO:0030667; C:secretory granule membrane; TAS:Reactome.
DR GO; GO:0042605; F:peptide antigen binding; IDA:UniProtKB.
DR GO; GO:0051087; F:protein-folding chaperone binding; IPI:UniProtKB.
DR GO; GO:0005102; F:signaling receptor binding; IPI:UniProtKB.
DR GO; GO:0046977; F:TAP binding; IDA:UniProtKB.
DR GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW.
DR GO; GO:0002486; P:antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent; IDA:UniProtKB.
DR GO; GO:0002476; P:antigen processing and presentation of endogenous peptide antigen via MHC class Ib; IBA:GO_Central.
DR GO; GO:0006952; P:defense response; TAS:UniProtKB.
DR GO; GO:0016045; P:detection of bacterium; IMP:UniProtKB.
DR GO; GO:0006955; P:immune response; IMP:UniProtKB.
DR GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR GO; GO:0001916; P:positive regulation of T cell mediated cytotoxicity; IDA:UniProtKB.
DR GO; GO:0042270; P:protection from natural killer cell mediated cytotoxicity; IDA:UniProtKB.
DR GO; GO:2001198; P:regulation of dendritic cell differentiation; IMP:BHF-UCL.
DR GO; GO:0032655; P:regulation of interleukin-12 production; IMP:BHF-UCL.
DR GO; GO:0032675; P:regulation of interleukin-6 production; IMP:BHF-UCL.
DR GO; GO:0002667; P:regulation of T cell anergy; IMP:BHF-UCL.
DR CDD; cd21026; IgC1_MHC_Ia_HLA-B; 1.
DR Gene3D; 2.60.40.10; Immunoglobulins; 1.
DR Gene3D; 3.30.500.10; MHC class I-like antigen recognition-like; 1.
DR InterPro; IPR007110; Ig-like_dom.
DR InterPro; IPR036179; Ig-like_dom_sf.
DR InterPro; IPR013783; Ig-like_fold.
DR InterPro; IPR003006; Ig/MHC_CS.
DR InterPro; IPR003597; Ig_C1-set.
DR InterPro; IPR011161; MHC_I-like_Ag-recog.
DR InterPro; IPR037055; MHC_I-like_Ag-recog_sf.
DR InterPro; IPR011162; MHC_I/II-like_Ag-recog.
DR InterPro; IPR001039; MHC_I_a_a1/a2.
DR InterPro; IPR010579; MHC_I_a_C.
DR PANTHER; PTHR16675:SF270; HLA CLASS I HISTOCOMPATIBILITY ANTIGEN, B ALPHA CHAIN; 1.
DR PANTHER; PTHR16675; MHC CLASS I-RELATED; 1.
DR Pfam; PF07654; C1-set; 1.
DR Pfam; PF00129; MHC_I; 1.
DR Pfam; PF06623; MHC_I_C; 1.
DR PRINTS; PR01638; MHCCLASSI.
DR SMART; SM00407; IGc1; 1.
DR SUPFAM; SSF48726; Immunoglobulin; 1.
DR SUPFAM; SSF54452; MHC antigen-recognition domain; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
DR PROSITE; PS00290; IG_MHC; 1.
PE 1: Evidence at protein level;
KW 3D-structure; Adaptive immunity; Cell membrane; Direct protein sequencing;
KW Disulfide bond; Endoplasmic reticulum; Glycoprotein;
KW Host-virus interaction; Immunity; Innate immunity; Membrane; MHC I;
KW Phosphoprotein; Reference proteome; Signal; Transmembrane;
KW Transmembrane helix.
FT SIGNAL 1..24
FT /evidence="ECO:0000269|PubMed:518865"
FT CHAIN 25..362
FT /note="HLA class I histocompatibility antigen, B alpha
FT chain"
FT /id="PRO_0000018833"
FT TOPO_DOM 25..309
FT /note="Extracellular"
FT /evidence="ECO:0000255"
FT TRANSMEM 310..333
FT /note="Helical"
FT /evidence="ECO:0000255"
FT TOPO_DOM 334..362
FT /note="Cytoplasmic"
FT /evidence="ECO:0000255"
FT DOMAIN 209..295
FT /note="Ig-like C1-type"
FT REGION 3..11
FT /note="VL9 epitope"
FT /evidence="ECO:0000269|PubMed:37264229"
FT REGION 25..114
FT /note="Alpha-1"
FT /evidence="ECO:0000255"
FT REGION 115..206
FT /note="Alpha-2"
FT /evidence="ECO:0000255"
FT REGION 207..298
FT /note="Alpha-3"
FT /evidence="ECO:0000255"
FT REGION 299..309
FT /note="Connecting peptide"
FT /evidence="ECO:0000255"
FT REGION 337..362
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT MOTIF 101..107
FT /note="Bw6 motif"
FT /evidence="ECO:0000269|PubMed:25480565"
FT COMPBIAS 339..362
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT BINDING 87
FT /ligand="a peptide antigen"
FT /ligand_id="ChEBI:CHEBI:166823"
FT /ligand_note="pathogen-derived peptide antigen"
FT /evidence="ECO:0000269|PubMed:25808313"
FT BINDING 108
FT /ligand="a peptide antigen"
FT /ligand_id="ChEBI:CHEBI:166823"
FT /ligand_note="pathogen-derived peptide antigen"
FT /evidence="ECO:0000269|PubMed:25808313"
FT BINDING 167
FT /ligand="a peptide antigen"
FT /ligand_id="ChEBI:CHEBI:166823"
FT /ligand_note="pathogen-derived peptide antigen"
FT /evidence="ECO:0000269|PubMed:25808313"
FT BINDING 170
FT /ligand="a peptide antigen"
FT /ligand_id="ChEBI:CHEBI:166823"
FT /ligand_note="pathogen-derived peptide antigen"
FT /evidence="ECO:0000269|PubMed:25808313"
FT BINDING 176
FT /ligand="a peptide antigen"
FT /ligand_id="ChEBI:CHEBI:166823"
FT /ligand_note="pathogen-derived peptide antigen"
FT /evidence="ECO:0000269|PubMed:25808313"
FT BINDING 183
FT /ligand="a peptide antigen"
FT /ligand_id="ChEBI:CHEBI:166823"
FT /ligand_note="pathogen-derived peptide antigen"
FT /evidence="ECO:0000269|PubMed:25808313"
FT BINDING 195
FT /ligand="a peptide antigen"
FT /ligand_id="ChEBI:CHEBI:166823"
FT /ligand_note="pathogen-derived peptide antigen"
FT /evidence="ECO:0000269|PubMed:25808313"
FT CARBOHYD 110
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000269|PubMed:19159218"
FT DISULFID 125..188
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT ECO:0000269|PubMed:17057332, ECO:0000269|PubMed:25808313,
FT ECO:0000269|PubMed:29531227"
FT DISULFID 227..283
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT ECO:0000269|PubMed:17057332, ECO:0000269|PubMed:25808313,
FT ECO:0000269|PubMed:29531227"
FT VARIANT 2
FT /note="L -> R (in allele B*13:02, allele B*15:01, allele
FT B*18:01, allele B*27:01, allele B*27:05, allele B*35:01,
FT allele B*37:01, allele B*40:01, allele B*40:02, allele
FT B*41:01, allele B*44:02, allele B*45:01, allele B*46:01,
FT allele B*47:01, allele B*49:01, allele B*50:01, allele
FT B*51:01, allele B*52:01, allele B*53:01, allele B*54:01,
FT allele B*55:01, allele B*56:01, allele B*57:01, allele
FT B*58:01, allele B*59:01, allele B*78:01 and allele B*82:01;
FT dbSNP:rs9266206)"
FT /evidence="ECO:0000269|PubMed:10395103,
FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1362296,
FT ECO:0000269|PubMed:1385528, ECO:0000269|PubMed:1431115,
FT ECO:0000269|PubMed:1481202, ECO:0000269|PubMed:1691230,
FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:1737933,
FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:2251138,
FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2437025,
FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:2715640,
FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:2995352,
FT ECO:0000269|PubMed:3011411, ECO:0000269|PubMed:3257938,
FT ECO:0000269|PubMed:3489755, ECO:0000269|PubMed:7517584,
FT ECO:0000269|PubMed:7521976, ECO:0000269|PubMed:7558929,
FT ECO:0000269|PubMed:8362411, ECO:0000269|PubMed:8423049,
FT ECO:0000269|PubMed:8740766, ECO:0000269|PubMed:8773315,
FT ECO:0000269|Ref.37, ECO:0000269|Ref.38, ECO:0000269|Ref.40,
FT ECO:0000269|Ref.42, ECO:0000269|Ref.44, ECO:0000269|Ref.46,
FT ECO:0000269|Ref.47"
FT /id="VAR_082483"
FT VARIANT 4
FT /note="M -> T (in allele B*13:02, allele B*15:01, allele
FT B*18:01, allele B*27:01, allele B*27:05, allele B*35:01,
FT allele B*37:01, allele B*40:01, allele B*40:02, allele
FT B*41:01, allele B*44:02, allele B*45:01, allele B*46:01,
FT allele B*47:01, allele B*49:01, allele B*50:01, allele
FT B*51:01, allele B*52:01, allele B*53:01, allele B*54:01,
FT allele B*55:01, allele B*56:01, allele B*57:01, allele
FT B*58:01, allele B*59:01, allele B*78:01 and allele B*82:01;
FT dbSNP:rs1050458)"
FT /evidence="ECO:0000269|PubMed:10395103,
FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1362296,
FT ECO:0000269|PubMed:1385528, ECO:0000269|PubMed:1431115,
FT ECO:0000269|PubMed:1481202, ECO:0000269|PubMed:1691230,
FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:1737933,
FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:2251138,
FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2437025,
FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:2715640,
FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:2995352,
FT ECO:0000269|PubMed:3011411, ECO:0000269|PubMed:3257938,
FT ECO:0000269|PubMed:3489755, ECO:0000269|PubMed:7517584,
FT ECO:0000269|PubMed:7521976, ECO:0000269|PubMed:7558929,
FT ECO:0000269|PubMed:8362411, ECO:0000269|PubMed:8423049,
FT ECO:0000269|PubMed:8740766, ECO:0000269|PubMed:8773315,
FT ECO:0000269|Ref.37, ECO:0000269|Ref.38, ECO:0000269|Ref.40,
FT ECO:0000269|Ref.42, ECO:0000269|Ref.44, ECO:0000269|Ref.46,
FT ECO:0000269|Ref.47"
FT /id="VAR_082484"
FT VARIANT 9
FT /note="V -> L (in allele B*13:02, allele B*18:01, allele
FT B*27:01, allele B*27:05, allele B*37:01, allele B*40:02,
FT allele B*44:02, allele B*47:01, allele B*54:01, allele
FT B*55:01, allele B*56:01, allele B*59:01 and allele B*82:01;
FT dbSNP:rs1050462)"
FT /evidence="ECO:0000269|PubMed:12622774,
FT ECO:0000269|PubMed:1362296, ECO:0000269|PubMed:1481202,
FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2715640,
FT ECO:0000269|PubMed:3011411, ECO:0000269|PubMed:3257938,
FT ECO:0000269|PubMed:3489755, ECO:0000269|PubMed:7558929,
FT ECO:0000269|PubMed:8362411, ECO:0000269|Ref.37,
FT ECO:0000269|Ref.38, ECO:0000269|Ref.42, ECO:0000269|Ref.44,
FT ECO:0000269|Ref.46, ECO:0000269|Ref.47"
FT /id="VAR_082485"
FT VARIANT 14
FT /note="S -> W (in allele B*13:02, allele B*18:01, allele
FT B*27:01, allele B*27:05, allele B*35:01, allele B*37:01,
FT allele B*40:02, allele B*44:02, allele B*47:01, allele
FT B*51:01, allele B*52:01, allele B*53:01, allele B*54:01,
FT allele B*55:01, allele B*56:01, allele B*57:01, allele
FT B*58:01, allele B*59:01, allele B*78:01, allele B*81:01 and
FT allele B*82:01; dbSNP:rs1131156)"
FT /evidence="ECO:0000269|PubMed:10395103,
FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1362296,
FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1481202,
FT ECO:0000269|PubMed:1691230, ECO:0000269|PubMed:1699887,
FT ECO:0000269|PubMed:1737933, ECO:0000269|PubMed:21585707,
FT ECO:0000269|PubMed:2251138, ECO:0000269|PubMed:2320591,
FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:2715640,
FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:2995352,
FT ECO:0000269|PubMed:3011411, ECO:0000269|PubMed:3257938,
FT ECO:0000269|PubMed:3489755, ECO:0000269|PubMed:7558929,
FT ECO:0000269|PubMed:8362411, ECO:0000269|PubMed:8740766,
FT ECO:0000269|PubMed:8847228, ECO:0000269|PubMed:8851728,
FT ECO:0000269|Ref.37, ECO:0000269|Ref.38, ECO:0000269|Ref.40,
FT ECO:0000269|Ref.42, ECO:0000269|Ref.44, ECO:0000269|Ref.46,
FT ECO:0000269|Ref.47"
FT /id="VAR_082486"
FT VARIANT 15
FT /note="A -> G (in allele B*13:02, allele B*15:01, allele
FT B*18:01, allele B*27:01, allele B*27:05, allele B*35:01,
FT allele B*37:01, allele B*40:02, allele B*44:02, allele
FT B*46:01, allele B*47:01, allele B*51:01, allele B*52:01,
FT allele B*53:01, allele B*54:01, allele B*55:01, allele
FT B*56:01, allele B*57:01, allele B*58:01, allele B*59:01,
FT allele B*78:01, allele B*81:01 and allele B*82:01;
FT dbSNP:rs1131159)"
FT /evidence="ECO:0000269|PubMed:10395103,
FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1362296,
FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1481202,
FT ECO:0000269|PubMed:1691230, ECO:0000269|PubMed:1699887,
FT ECO:0000269|PubMed:1737933, ECO:0000269|PubMed:21585707,
FT ECO:0000269|PubMed:2251138, ECO:0000269|PubMed:2320591,
FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:2715640,
FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:2995352,
FT ECO:0000269|PubMed:3011411, ECO:0000269|PubMed:3257938,
FT ECO:0000269|PubMed:3489755, ECO:0000269|PubMed:7521976,
FT ECO:0000269|PubMed:7558929, ECO:0000269|PubMed:8362411,
FT ECO:0000269|PubMed:8423049, ECO:0000269|PubMed:8740766,
FT ECO:0000269|PubMed:8773315, ECO:0000269|PubMed:8847228,
FT ECO:0000269|PubMed:8851728, ECO:0000269|Ref.37,
FT ECO:0000269|Ref.38, ECO:0000269|Ref.40, ECO:0000269|Ref.42,
FT ECO:0000269|Ref.44, ECO:0000269|Ref.46, ECO:0000269|Ref.47"
FT /id="VAR_082487"
FT VARIANT 17
FT /note="L -> V (in allele B*13:02, allele B*18:01, allele
FT B*27:01, allele B*27:05, allele B*35:01, allele B*37:01,
FT allele B*40:02, allele B*44:02, allele B*47:01, allele
FT B*51:01, allele B*52:01, allele B*53:01, allele B*57:01,
FT allele B*58:01, allele B*78:01 and allele B*81:01;
FT dbSNP:rs1131165)"
FT /evidence="ECO:0000269|PubMed:10395103,
FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1362296,
FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1481202,
FT ECO:0000269|PubMed:1691230, ECO:0000269|PubMed:1699887,
FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:2251138,
FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2714852,
FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:2788131,
FT ECO:0000269|PubMed:2995352, ECO:0000269|PubMed:3011411,
FT ECO:0000269|PubMed:3257938, ECO:0000269|PubMed:3489755,
FT ECO:0000269|PubMed:7558929, ECO:0000269|PubMed:8847228,
FT ECO:0000269|PubMed:8851728, ECO:0000269|Ref.37,
FT ECO:0000269|Ref.42, ECO:0000269|Ref.44, ECO:0000269|Ref.46"
FT /id="VAR_082488"
FT VARIANT 33
FT /note="Y -> D (in allele B*08:01; associated with increased
FT risk for rheumatoid arthritis; dbSNP:rs2596492)"
FT /evidence="ECO:0000269|PubMed:12622774,
FT ECO:0000269|PubMed:22286218, ECO:0000269|PubMed:2715640,
FT ECO:0000269|Ref.48"
FT /id="VAR_082489"
FT VARIANT 33
FT /note="Y -> H (in allele B*18:01, allele B*27:01, allele
FT B*27:05, allele B*37:01, allele B*40:01, allele B*40:02,
FT allele B*41:01, allele B*45:01, allele B*49:01, allele
FT B*50:01 and allele B*73:01; dbSNP:rs2596492)"
FT /evidence="ECO:0000269|PubMed:12622774,
FT ECO:0000269|PubMed:1362296, ECO:0000269|PubMed:1385528,
FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1481202,
FT ECO:0000269|PubMed:21868630, ECO:0000269|PubMed:2320591,
FT ECO:0000269|PubMed:2437025, ECO:0000269|PubMed:2715640,
FT ECO:0000269|PubMed:3011411, ECO:0000269|PubMed:3489755,
FT ECO:0000269|PubMed:7517584, ECO:0000269|PubMed:7517915,
FT ECO:0000269|PubMed:7524186, ECO:0000269|PubMed:8547229,
FT ECO:0000269|Ref.37, ECO:0000269|Ref.44, ECO:0000269|Ref.46"
FT /id="VAR_082490"
FT VARIANT 35
FT /note="S -> A (in allele B*08:01, allele B*13:02, allele
FT B*15:01, allele B*35:01, allele B*40:01, allele B*41:01,
FT allele B*44:02, allele B*45:01, allele B*46:01, allele
FT B*47:01, allele B*49:01, allele B*50:01, allele B*51:01,
FT allele B*52:01, allele B*53:01, allele B*54:01, allele
FT B*55:01, allele B*56:01, allele B*57:01, allele B*58:01,
FT allele B*59:01, allele B*78:01 and allele B*82:01;
FT dbSNP:rs1131170)"
FT /evidence="ECO:0000269|PubMed:10395103,
FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1385528,
FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1691230,
FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:1737933,
FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:2251138,
FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2437025,
FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:2715640,
FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:2995352,
FT ECO:0000269|PubMed:3257938, ECO:0000269|PubMed:7517584,
FT ECO:0000269|PubMed:7521976, ECO:0000269|PubMed:7558929,
FT ECO:0000269|PubMed:8362411, ECO:0000269|PubMed:8423049,
FT ECO:0000269|PubMed:8740766, ECO:0000269|PubMed:8773315,
FT ECO:0000269|Ref.37, ECO:0000269|Ref.38, ECO:0000269|Ref.40,
FT ECO:0000269|Ref.42, ECO:0000269|Ref.44, ECO:0000269|Ref.47,
FT ECO:0000269|Ref.48"
FT /id="VAR_082491"
FT VARIANT 36
FT /note="V -> M (in allele B*08:01, allele B*13:02, allele
FT B*15:01, allele B*35:01, allele B*40:01, allele B*41:01,
FT allele B*44:02, allele B*45:01, allele B*46:01, allele
FT B*47:01, allele B*49:01, allele B*50:01, allele B*51:01,
FT allele B*52:01, allele B*53:01, allele B*54:01, allele
FT B*55:01, allele B*56:01, allele B*57:01, allele B*58:01,
FT allele B*59:01, allele B*78:01 and allele B*82:01;
FT dbSNP:rs1050486)"
FT /evidence="ECO:0000269|PubMed:10395103,
FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1385528,
FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1691230,
FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:1737933,
FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:2251138,
FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2437025,
FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:2715640,
FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:2995352,
FT ECO:0000269|PubMed:3257938, ECO:0000269|PubMed:7517584,
FT ECO:0000269|PubMed:7521976, ECO:0000269|PubMed:7558929,
FT ECO:0000269|PubMed:8362411, ECO:0000269|PubMed:8423049,
FT ECO:0000269|PubMed:8740766, ECO:0000269|PubMed:8773315,
FT ECO:0000269|Ref.37, ECO:0000269|Ref.38, ECO:0000269|Ref.40,
FT ECO:0000269|Ref.42, ECO:0000269|Ref.44, ECO:0000269|Ref.47,
FT ECO:0000269|Ref.48"
FT /id="VAR_082492"
FT VARIANT 48
FT /note="S -> A (in allele B*15:01, allele B*35:01, allele
FT B*46:01, allele B*51:01, allele B*52:01, allele B*53:01,
FT allele B*54:01, allele B*55:01, allele B*56:01, allele
FT B*57:01, allele B*58:01, allele B*59:01 and allele B*78:01;
FT dbSNP:rs713031)"
FT /evidence="ECO:0000269|PubMed:10395103,
FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1431115,
FT ECO:0000269|PubMed:1691230, ECO:0000269|PubMed:1699887,
FT ECO:0000269|PubMed:1737933, ECO:0000269|PubMed:21585707,
FT ECO:0000269|PubMed:2251138, ECO:0000269|PubMed:2320591,
FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:2715640,
FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:2995352,
FT ECO:0000269|PubMed:7521976, ECO:0000269|PubMed:8362411,
FT ECO:0000269|PubMed:8423049, ECO:0000269|PubMed:8773315,
FT ECO:0000269|Ref.38, ECO:0000269|Ref.44, ECO:0000269|Ref.47"
FT /id="VAR_082493"
FT VARIANT 48
FT /note="S -> T (in allele B*13:02, allele B*27:01, allele
FT B*27:05, allele B*40:01, allele B*40:02, allele B*41:01,
FT allele B*44:02, allele B*45:01, allele B*47:01, allele
FT B*49:01, allele B*50:01 and allele B*73:01;
FT dbSNP:rs713031)"
FT /evidence="ECO:0000269|PubMed:12622774,
FT ECO:0000269|PubMed:1362296, ECO:0000269|PubMed:1385528,
FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1481202,
FT ECO:0000269|PubMed:21868630, ECO:0000269|PubMed:2437025,
FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:3011411,
FT ECO:0000269|PubMed:3257938, ECO:0000269|PubMed:3489755,
FT ECO:0000269|PubMed:7517584, ECO:0000269|PubMed:7517915,
FT ECO:0000269|PubMed:7524186, ECO:0000269|PubMed:7558929,
FT ECO:0000269|PubMed:8547229, ECO:0000269|Ref.37,
FT ECO:0000269|Ref.42, ECO:0000269|Ref.46"
FT /id="VAR_082494"
FT VARIANT 54
FT /note="D -> G (in allele B*18:01; dbSNP:rs9266183)"
FT /evidence="ECO:0000269|PubMed:12622774,
FT ECO:0000269|PubMed:2715640"
FT /id="VAR_082495"
FT VARIANT 56
FT /note="Q -> L (in allele B*27:01, allele B*27:05, allele
FT B*40:01, allele B*40:02, allele B*41:01, allele B*44:02,
FT allele B*45:01, allele B*47:01, allele B*49:01 and allele
FT B*50:01; dbSNP:rs1050518)"
FT /evidence="ECO:0000269|PubMed:12622774,
FT ECO:0000269|PubMed:1362296, ECO:0000269|PubMed:1385528,
FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1481202,
FT ECO:0000269|PubMed:2437025, ECO:0000269|PubMed:2715640,
FT ECO:0000269|PubMed:3011411, ECO:0000269|PubMed:3257938,
FT ECO:0000269|PubMed:3489755, ECO:0000269|PubMed:7517584,
FT ECO:0000269|Ref.37, ECO:0000269|Ref.42, ECO:0000269|Ref.46"
FT /id="VAR_082496"
FT VARIANT 65
FT /note="A -> T (in allele B*13:02, allele B*40:01, allele
FT B*40:02, allele B*41:01, allele B*44:02, allele B*45:01,
FT allele B*47:01, allele B*49:01 and allele B*50:01;
FT dbSNP:rs1050529)"
FT /evidence="ECO:0000269|PubMed:12622774,
FT ECO:0000269|PubMed:1362296, ECO:0000269|PubMed:1385528,
FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1481202,
FT ECO:0000269|PubMed:2437025, ECO:0000269|PubMed:2715640,
FT ECO:0000269|PubMed:3257938, ECO:0000269|PubMed:7517584,
FT ECO:0000269|PubMed:7558929, ECO:0000269|Ref.37,
FT ECO:0000269|Ref.42"
FT /id="VAR_082497"
FT VARIANT 69
FT /note="E -> G (in allele B*54:01; dbSNP:rs41562914)"
FT /evidence="ECO:0000269|PubMed:1737933"
FT /id="VAR_082498"
FT VARIANT 69
FT /note="E -> K (in allele B*40:01, allele B*40:02, allele
FT B*41:01, allele B*44:02, allele B*45:01, allele B*47:01,
FT allele B*49:01 and allele B*50:01; dbSNP:rs9266178)"
FT /evidence="ECO:0000269|PubMed:12622774,
FT ECO:0000269|PubMed:1362296, ECO:0000269|PubMed:1385528,
FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1481202,
FT ECO:0000269|PubMed:2437025, ECO:0000269|PubMed:2715640,
FT ECO:0000269|PubMed:3257938, ECO:0000269|PubMed:7517584,
FT ECO:0000269|Ref.37, ECO:0000269|Ref.42"
FT /id="VAR_082499"
FT VARIANT 69
FT /note="E -> M (in allele B*13:02, allele B*15:01, allele
FT B*46:01 and allele B*57:01; requires 2 nucleotide
FT substitutions)"
FT /evidence="ECO:0000269|PubMed:2251138,
FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2715640,
FT ECO:0000269|PubMed:3257938, ECO:0000269|PubMed:7521976,
FT ECO:0000269|PubMed:7558929, ECO:0000269|PubMed:8423049,
FT ECO:0000269|PubMed:8773315"
FT /id="VAR_082500"
FT VARIANT 69
FT /note="E -> T (in allele B*18:01, allele B*35:01, allele
FT B*37:01, allele B*51:01, allele B*52:01, allele B*53:01,
FT allele B*58:01 and allele B*78:01; requires 2 nucleotide
FT substitutions)"
FT /evidence="ECO:0000269|PubMed:10395103,
FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1431115,
FT ECO:0000269|PubMed:1691230, ECO:0000269|PubMed:1699887,
FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:2320591,
FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:2715640,
FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:2995352,
FT ECO:0000269|Ref.37, ECO:0000269|Ref.44"
FT /id="VAR_082501"
FT VARIANT 70
FT /note="E -> A (in allele B*13:02, allele B*15:01, allele
FT B*46:01 and allele B*57:01; dbSNP:rs1050538)"
FT /evidence="ECO:0000269|PubMed:2251138,
FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2715640,
FT ECO:0000269|PubMed:3257938, ECO:0000269|PubMed:7521976,
FT ECO:0000269|PubMed:7558929, ECO:0000269|PubMed:8423049,
FT ECO:0000269|PubMed:8773315"
FT /id="VAR_082502"
FT VARIANT 76
FT /note="I -> V (in allele B*54:01; dbSNP:rs145974360)"
FT /evidence="ECO:0000269|PubMed:1737933"
FT /id="VAR_082503"
FT VARIANT 86
FT /note="R -> G (in allele B*57:01 and allele B*58:01;
FT dbSNP:rs141484466)"
FT /evidence="ECO:0000269|PubMed:10395103,
FT ECO:0000269|PubMed:2251138, ECO:0000269|PubMed:2320591,
FT ECO:0000269|PubMed:2995352"
FT /id="VAR_082504"
FT VARIANT 87
FT /note="N -> E (in allele B*13:02, allele B*15:01, allele
FT B*27:01, allele B*27:05, allele B*37:01, allele B*39:02,
FT allele B*40:01, allele B*40:02, allele B*41:01, allele
FT B*44:02, allele B*45:01, allele B*46:01, allele B*47:01,
FT allele B*48:01, allele B*49:01, allele B*50:01, allele
FT B*52:01, allele B*57:01 and allele B*58:01; requires 2
FT nucleotide substitutions)"
FT /evidence="ECO:0000269|PubMed:10395103,
FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1317015,
FT ECO:0000269|PubMed:1362296, ECO:0000269|PubMed:1385528,
FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1481202,
FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:2251138,
FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2437025,
FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:2995352,
FT ECO:0000269|PubMed:3011411, ECO:0000269|PubMed:3257938,
FT ECO:0000269|PubMed:3489755, ECO:0000269|PubMed:7517584,
FT ECO:0000269|PubMed:7521976, ECO:0000269|PubMed:7558929,
FT ECO:0000269|PubMed:7725307, ECO:0000269|PubMed:8420828,
FT ECO:0000269|PubMed:8423049, ECO:0000269|PubMed:8773315,
FT ECO:0000269|Ref.37, ECO:0000269|Ref.42, ECO:0000269|Ref.44,
FT ECO:0000269|Ref.46"
FT /id="VAR_082505"
FT VARIANT 89
FT /note="Q -> R (in allele B*57:01 and allele B*58:01;
FT dbSNP:rs1131201)"
FT /evidence="ECO:0000269|PubMed:10395103,
FT ECO:0000269|PubMed:2251138, ECO:0000269|PubMed:2320591,
FT ECO:0000269|PubMed:2995352"
FT /id="VAR_082506"
FT VARIANT 90
FT /note="I -> K (in allele B*46:01)"
FT /evidence="ECO:0000269|PubMed:2715640"
FT /id="VAR_082507"
FT VARIANT 90
FT /note="I -> N (in allele B*57:01 and allele B*58:01;
FT dbSNP:rs1131202)"
FT /evidence="ECO:0000269|PubMed:10395103,
FT ECO:0000269|PubMed:2251138, ECO:0000269|PubMed:2320591,
FT ECO:0000269|PubMed:2995352"
FT /id="VAR_082508"
FT VARIANT 91
FT /note="Y -> C (in allele B*14:01, allele B*27:01, allele
FT B*27:05, allele B*38:01 and allele B*73:01;
FT dbSNP:rs1071816)"
FT /evidence="ECO:0000269|PubMed:21868630,
FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:3011411,
FT ECO:0000269|PubMed:3489755, ECO:0000269|PubMed:7517915,
FT ECO:0000269|PubMed:7524186, ECO:0000269|PubMed:7725307,
FT ECO:0000269|PubMed:8547229, ECO:0000269|Ref.41,
FT ECO:0000269|Ref.46"
FT /id="VAR_082509"
FT VARIANT 91
FT /note="Y -> F (in allele B*08:01, allele B*35:01, allele
FT B*51:01, allele B*53:01, allele B*59:01 and allele B*78:01;
FT dbSNP:rs1071816)"
FT /evidence="ECO:0000269|PubMed:12622774,
FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1691230,
FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:2320591,
FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:2715640,
FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:8362411,
FT ECO:0000269|Ref.38, ECO:0000269|Ref.44, ECO:0000269|Ref.48"
FT /id="VAR_082510"
FT VARIANT 91
FT /note="Y -> M (in allele B*57:01 and allele B*58:01;
FT requires 2 nucleotide substitutions)"
FT /evidence="ECO:0000269|PubMed:10395103,
FT ECO:0000269|PubMed:2251138, ECO:0000269|PubMed:2320591,
FT ECO:0000269|PubMed:2995352"
FT /id="VAR_082511"
FT VARIANT 91
FT /note="Y -> S (in allele B*13:02, allele B*15:01, allele
FT B*18:01, allele B*37:01, allele B*39:02, allele B*40:01,
FT allele B*40:02, allele B*41:01, allele B*44:02, allele
FT B*45:01, allele B*47:01, allele B*48:01, allele B*49:01,
FT allele B*50:01 and allele B*52:01; dbSNP:rs1071816)"
FT /evidence="ECO:0000269|PubMed:12622774,
FT ECO:0000269|PubMed:1317015, ECO:0000269|PubMed:1362296,
FT ECO:0000269|PubMed:1385528, ECO:0000269|PubMed:1431115,
FT ECO:0000269|PubMed:1481202, ECO:0000269|PubMed:21585707,
FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2437025,
FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:3257938,
FT ECO:0000269|PubMed:7517584, ECO:0000269|PubMed:7521976,
FT ECO:0000269|PubMed:7558929, ECO:0000269|PubMed:7725307,
FT ECO:0000269|PubMed:8420828, ECO:0000269|PubMed:8423049,
FT ECO:0000269|PubMed:8773315, ECO:0000269|Ref.37,
FT ECO:0000269|Ref.42, ECO:0000269|Ref.44"
FT /id="VAR_082512"
FT VARIANT 93
FT /note="A -> R (in allele B*46:01; requires 2 nucleotide
FT substitutions)"
FT /evidence="ECO:0000269|PubMed:2715640"
FT /id="VAR_082513"
FT VARIANT 93
FT /note="A -> T (in allele B*08:01, allele B*13:02, allele
FT B*14:01, allele B*15:01, allele B*18:01, allele B*35:01,
FT allele B*37:01, allele B*38:01, allele B*39:02, allele
FT B*40:01, allele B*40:02, allele B*41:01, allele B*44:02,
FT allele B*45:01, allele B*47:01, allele B*48:01, allele
FT B*49:01, allele B*50:01, allele B*51:01, allele B*52:01,
FT allele B*53:01, allele B*59:01 and allele B*78:01;
FT dbSNP:rs1131204)"
FT /evidence="ECO:0000269|PubMed:12622774,
FT ECO:0000269|PubMed:1317015, ECO:0000269|PubMed:1362296,
FT ECO:0000269|PubMed:1385528, ECO:0000269|PubMed:1431115,
FT ECO:0000269|PubMed:1481202, ECO:0000269|PubMed:1691230,
FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:21585707,
FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2437025,
FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:2715640,
FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:3257938,
FT ECO:0000269|PubMed:7517584, ECO:0000269|PubMed:7521976,
FT ECO:0000269|PubMed:7558929, ECO:0000269|PubMed:7725307,
FT ECO:0000269|PubMed:8362411, ECO:0000269|PubMed:8420828,
FT ECO:0000269|PubMed:8423049, ECO:0000269|PubMed:8773315,
FT ECO:0000269|Ref.37, ECO:0000269|Ref.38, ECO:0000269|Ref.41,
FT ECO:0000269|Ref.42, ECO:0000269|Ref.44, ECO:0000269|Ref.48"
FT /id="VAR_082514"
FT VARIANT 94
FT /note="Q -> K (in allele B*27:01, allele B*27:05 and allele
FT B*73:01; dbSNP:rs1071817)"
FT /evidence="ECO:0000269|PubMed:21868630,
FT ECO:0000269|PubMed:3011411, ECO:0000269|PubMed:3489755,
FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7524186,
FT ECO:0000269|PubMed:8547229, ECO:0000269|Ref.46"
FT /id="VAR_082515"
FT VARIANT 94
FT /note="Q -> N (in allele B*08:01, allele B*13:02, allele
FT B*14:01, allele B*15:01, allele B*18:01, allele B*35:01,
FT allele B*37:01, allele B*38:01, allele B*39:02, allele
FT B*40:01, allele B*40:02, allele B*41:01, allele B*44:02,
FT allele B*45:01, allele B*47:01, allele B*48:01, allele
FT B*49:01, allele B*50:01, allele B*51:01, allele B*52:01,
FT allele B*53:01, allele B*59:01 and allele B*78:01; requires
FT 2 nucleotide substitutions)"
FT /evidence="ECO:0000269|PubMed:12622774,
FT ECO:0000269|PubMed:1317015, ECO:0000269|PubMed:1362296,
FT ECO:0000269|PubMed:1385528, ECO:0000269|PubMed:1431115,
FT ECO:0000269|PubMed:1481202, ECO:0000269|PubMed:1691230,
FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:21585707,
FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2437025,
FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:2715640,
FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:3257938,
FT ECO:0000269|PubMed:7517584, ECO:0000269|PubMed:7521976,
FT ECO:0000269|PubMed:7558929, ECO:0000269|PubMed:7725307,
FT ECO:0000269|PubMed:8362411, ECO:0000269|PubMed:8420828,
FT ECO:0000269|PubMed:8423049, ECO:0000269|PubMed:8773315,
FT ECO:0000269|Ref.37, ECO:0000269|Ref.38, ECO:0000269|Ref.41,
FT ECO:0000269|Ref.42, ECO:0000269|Ref.44, ECO:0000269|Ref.48"
FT /id="VAR_082516"
FT VARIANT 94
FT /note="Q -> S (in allele B*57:01 and allele B*58:01;
FT requires 2 nucleotide substitutions)"
FT /evidence="ECO:0000269|PubMed:10395103,
FT ECO:0000269|PubMed:2251138, ECO:0000269|PubMed:2320591,
FT ECO:0000269|PubMed:2995352"
FT /id="VAR_082517"
FT VARIANT 95
FT /note="A -> T (in allele B*08:01, allele B*13:02, allele
FT B*14:01, allele B*15:01, allele B*18:01, allele B*35:01,
FT allele B*37:01, allele B*38:01, allele B*39:02, allele
FT B*40:01, allele B*40:02, allele B*41:01, allele B*44:02,
FT allele B*45:01, allele B*47:01, allele B*48:01, allele
FT B*49:01, allele B*50:01, allele B*51:01, allele B*52:01,
FT allele B*53:01, allele B*59:01 and allele B*78:01;
FT dbSNP:rs1131213)"
FT /evidence="ECO:0000269|PubMed:12622774,
FT ECO:0000269|PubMed:1317015, ECO:0000269|PubMed:1362296,
FT ECO:0000269|PubMed:1385528, ECO:0000269|PubMed:1431115,
FT ECO:0000269|PubMed:1481202, ECO:0000269|PubMed:1691230,
FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:21585707,
FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2437025,
FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:2715640,
FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:3257938,
FT ECO:0000269|PubMed:7517584, ECO:0000269|PubMed:7521976,
FT ECO:0000269|PubMed:7558929, ECO:0000269|PubMed:7725307,
FT ECO:0000269|PubMed:8362411, ECO:0000269|PubMed:8420828,
FT ECO:0000269|PubMed:8423049, ECO:0000269|PubMed:8773315,
FT ECO:0000269|Ref.37, ECO:0000269|Ref.38, ECO:0000269|Ref.41,
FT ECO:0000269|Ref.42, ECO:0000269|Ref.44, ECO:0000269|Ref.48"
FT /id="VAR_082518"
FT VARIANT 98
FT /note="D -> Y (in allele B*13:02, allele B*15:01, allele
FT B*18:01, allele B*27:01, allele B*35:01, allele B*37:01,
FT allele B*38:01, allele B*40:01, allele B*40:02, allele
FT B*41:01, allele B*44:02, allele B*45:01, allele B*47:01,
FT allele B*48:01, allele B*49:01, allele B*50:01, allele
FT B*51:01, allele B*52:01, allele B*53:01, allele B*57:01,
FT allele B*58:01 and allele B*59:01; dbSNP:rs1131215)"
FT /evidence="ECO:0000269|PubMed:10395103,
FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1317015,
FT ECO:0000269|PubMed:1362296, ECO:0000269|PubMed:1385528,
FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1481202,
FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:21585707,
FT ECO:0000269|PubMed:2251138, ECO:0000269|PubMed:2320591,
FT ECO:0000269|PubMed:2437025, ECO:0000269|PubMed:2714852,
FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:2788131,
FT ECO:0000269|PubMed:2995352, ECO:0000269|PubMed:3257938,
FT ECO:0000269|PubMed:7517584, ECO:0000269|PubMed:7521976,
FT ECO:0000269|PubMed:7558929, ECO:0000269|PubMed:7725307,
FT ECO:0000269|PubMed:8362411, ECO:0000269|PubMed:8423049,
FT ECO:0000269|PubMed:8773315, ECO:0000269|Ref.37,
FT ECO:0000269|Ref.38, ECO:0000269|Ref.41, ECO:0000269|Ref.42,
FT ECO:0000269|Ref.44, ECO:0000269|Ref.46"
FT /id="VAR_082519"
FT VARIANT 100
FT /note="E -> V (in allele B*46:01 and allele B*73:01;
FT dbSNP:rs41553715)"
FT /evidence="ECO:0000269|PubMed:21868630,
FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:7517915,
FT ECO:0000269|PubMed:7524186, ECO:0000269|PubMed:8547229"
FT /id="VAR_082520"
FT VARIANT 101
FT /note="S -> D (in allele B*27:05, allele B*37:01 and allele
FT B*47:01; requires 2 nucleotide substitutions)"
FT /evidence="ECO:0000269|PubMed:12622774,
FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:3011411,
FT ECO:0000269|PubMed:3257938, ECO:0000269|PubMed:3489755,
FT ECO:0000269|Ref.37, ECO:0000269|Ref.44"
FT /id="VAR_082521"
FT VARIANT 101
FT /note="S -> G (in allele B*73:01; dbSNP:rs1131217)"
FT /evidence="ECO:0000269|PubMed:21868630,
FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7524186,
FT ECO:0000269|PubMed:8547229"
FT /id="VAR_082522"
FT VARIANT 101
FT /note="S -> N (in allele B*13:02, allele B*27:01, allele
FT B*38:01, allele B*44:02, allele B*49:01, allele B*51:01,
FT allele B*52:01, allele B*53:01, allele B*57:01, allele
FT B*58:01 and allele B*59:01; dbSNP:rs1050388)"
FT /evidence="ECO:0000269|PubMed:10395103,
FT ECO:0000269|PubMed:1385528, ECO:0000269|PubMed:1699887,
FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:2251138,
FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2714852,
FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:2995352,
FT ECO:0000269|PubMed:3257938, ECO:0000269|PubMed:7558929,
FT ECO:0000269|PubMed:7725307, ECO:0000269|PubMed:8362411,
FT ECO:0000269|Ref.38, ECO:0000269|Ref.41, ECO:0000269|Ref.46"
FT /id="VAR_082523"
FT VARIANT 104
FT /note="N -> I (in allele B*38:01, allele B*49:01, allele
FT B*51:01, allele B*52:01, allele B*53:01, allele B*57:01 and
FT allele B*59:01; part of Bw4 motif involved in the
FT recognition of KIR3DL1; dbSNP:rs1131223)"
FT /evidence="ECO:0000269|PubMed:1385528,
FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:21585707,
FT ECO:0000269|PubMed:22020283, ECO:0000269|PubMed:2251138,
FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:25480565,
FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:7725307,
FT ECO:0000269|Ref.41"
FT /id="VAR_082524"
FT VARIANT 104
FT /note="N -> T (in allele B*13:02, allele B*27:01, allele
FT B*27:05, allele B*37:01, allele B*44:02 and allele B*47:01;
FT dbSNP:rs1131223)"
FT /evidence="ECO:0000269|PubMed:12622774,
FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2715640,
FT ECO:0000269|PubMed:3011411, ECO:0000269|PubMed:3257938,
FT ECO:0000269|PubMed:3489755, ECO:0000269|PubMed:7558929,
FT ECO:0000269|Ref.37, ECO:0000269|Ref.42, ECO:0000269|Ref.44,
FT ECO:0000269|Ref.46"
FT /id="VAR_082525"
FT VARIANT 105
FT /note="L -> A (in allele B*13:02, allele B*27:01, allele
FT B*38:01, allele B*44:02, allele B*49:01, allele B*51:01,
FT allele B*52:01, allele B*53:01, allele B*57:01, allele
FT B*58:01 and allele B*59:01; requires 2 nucleotide
FT substitutions)"
FT /evidence="ECO:0000269|PubMed:10395103,
FT ECO:0000269|PubMed:1385528, ECO:0000269|PubMed:1699887,
FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:2251138,
FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2714852,
FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:2995352,
FT ECO:0000269|PubMed:3257938, ECO:0000269|PubMed:7558929,
FT ECO:0000269|PubMed:7725307, ECO:0000269|PubMed:8362411,
FT ECO:0000269|Ref.38, ECO:0000269|Ref.41, ECO:0000269|Ref.42,
FT ECO:0000269|Ref.46"
FT /id="VAR_082526"
FT VARIANT 106
FT /note="R -> L (in allele B*13:02, allele B*27:01, allele
FT B*27:05, allele B*37:01, allele B*38:01, allele B*44:02,
FT allele B*49:01, allele B*51:01, allele B*52:01, allele
FT B*53:01, allele B*57:01, allele B*58:01 and allele B*59:01;
FT dbSNP:rs3180379)"
FT /evidence="ECO:0000269|PubMed:10395103,
FT ECO:0000269|PubMed:1385528, ECO:0000269|PubMed:1699887,
FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:2251138,
FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2714852,
FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:2995352,
FT ECO:0000269|PubMed:3011411, ECO:0000269|PubMed:3257938,
FT ECO:0000269|PubMed:3489755, ECO:0000269|PubMed:7558929,
FT ECO:0000269|PubMed:7725307, ECO:0000269|PubMed:8362411,
FT ECO:0000269|Ref.37, ECO:0000269|Ref.38, ECO:0000269|Ref.41,
FT ECO:0000269|Ref.42, ECO:0000269|Ref.44, ECO:0000269|Ref.46"
FT /id="VAR_082527"
FT VARIANT 107
FT /note="G -> R (in allele B*13:02, allele B*27:01, allele
FT B*27:05, allele B*37:01, allele B*38:01, allele B*44:02,
FT allele B*47:01, allele B*49:01, allele B*51:01, allele
FT B*52:01, allele B*53:01, allele B*57:01, allele B*58:01 and
FT allele B*59:01; part of Bw4 motif involved in the
FT recognition of KIR3DL1; dbSNP:rs3180380)"
FT /evidence="ECO:0000269|PubMed:10395103,
FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1385528,
FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:21585707,
FT ECO:0000269|PubMed:22020283, ECO:0000269|PubMed:2251138,
FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:25480565,
FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:2715640,
FT ECO:0000269|PubMed:2995352, ECO:0000269|PubMed:3011411,
FT ECO:0000269|PubMed:3257938, ECO:0000269|PubMed:3489755,
FT ECO:0000269|PubMed:7558929, ECO:0000269|PubMed:7725307,
FT ECO:0000269|PubMed:8362411, ECO:0000269|Ref.37,
FT ECO:0000269|Ref.38, ECO:0000269|Ref.41, ECO:0000269|Ref.42,
FT ECO:0000269|Ref.44, ECO:0000269|Ref.46"
FT /id="VAR_082528"
FT VARIANT 114
FT /note="A -> D (in allele B*73:01; dbSNP:rs41559314)"
FT /evidence="ECO:0000269|PubMed:21868630,
FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7524186,
FT ECO:0000269|PubMed:8547229"
FT /id="VAR_082529"
FT VARIANT 118
FT /note="T -> I (in allele B*35:01, allele B*44:02, allele
FT B*53:01, allele B*57:01 and allele B*58:01;
FT dbSNP:rs12721827)"
FT /evidence="ECO:0000269|PubMed:10395103,
FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:2251138,
FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2715640,
FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:2995352,
FT ECO:0000269|Ref.42"
FT /id="VAR_082530"
FT VARIANT 119
FT /note="L -> I (in allele B*35:01, allele B*37:01, allele
FT B*44:02, allele B*53:01, allele B*57:01 and allele B*58:01;
FT dbSNP:rs12721829)"
FT /evidence="ECO:0000269|PubMed:10395103,
FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:2320591,
FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:2788131,
FT ECO:0000269|PubMed:2995352, ECO:0000269|Ref.37,
FT ECO:0000269|Ref.42, ECO:0000269|Ref.44"
FT /id="VAR_082531"
FT VARIANT 119
FT /note="L -> W (in allele B*13:02, allele B*41:01, allele
FT B*45:01, allele B*49:01, allele B*50:01, allele B*51:01,
FT allele B*52:01, allele B*54:01, allele B*55:01, allele
FT B*56:01, allele B*59:01, allele B*73:01 and allele
FT B*78:01)"
FT /evidence="ECO:0000269|PubMed:12622774,
FT ECO:0000269|PubMed:1385528, ECO:0000269|PubMed:1431115,
FT ECO:0000269|PubMed:1691230, ECO:0000269|PubMed:1737933,
FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:21868630,
FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2714852,
FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:3257938,
FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7524186,
FT ECO:0000269|PubMed:7558929, ECO:0000269|PubMed:8362411,
FT ECO:0000269|PubMed:8547229, ECO:0000269|Ref.37,
FT ECO:0000269|Ref.38, ECO:0000269|Ref.44, ECO:0000269|Ref.47"
FT /id="VAR_082532"
FT VARIANT 121
FT /note="S -> N (in allele B*27:01 and allele B*27:05;
FT dbSNP:rs1071652)"
FT /evidence="ECO:0000269|PubMed:3011411,
FT ECO:0000269|PubMed:3489755, ECO:0000269|Ref.46"
FT /id="VAR_082533"
FT VARIANT 121
FT /note="S -> R (in allele B*15:01, allele B*18:01, allele
FT B*35:01, allele B*37:01, allele B*38:01, allele B*39:02,
FT allele B*40:01, allele B*41:01, allele B*44:02, allele
FT B*45:01, allele B*46:01, allele B*47:01, allele B*49:01,
FT allele B*50:01, allele B*53:01, allele B*58:01, allele
FT B*67:01 and allele B*82:01; dbSNP:rs1140412)"
FT /evidence="ECO:0000269|PubMed:10395103,
FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1385528,
FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1699887,
FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2437025,
FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:2788131,
FT ECO:0000269|PubMed:2995352, ECO:0000269|PubMed:3257938,
FT ECO:0000269|PubMed:7517584, ECO:0000269|PubMed:7521976,
FT ECO:0000269|PubMed:7725307, ECO:0000269|PubMed:8420828,
FT ECO:0000269|PubMed:8423049, ECO:0000269|PubMed:8740766,
FT ECO:0000269|PubMed:8773315, ECO:0000269|Ref.37,
FT ECO:0000269|Ref.40, ECO:0000269|Ref.41, ECO:0000269|Ref.42,
FT ECO:0000269|Ref.44"
FT /id="VAR_082534"
FT VARIANT 121
FT /note="S -> T (in allele B*13:02, allele B*51:01, allele
FT B*52:01, allele B*54:01, allele B*55:01, allele B*56:01,
FT allele B*59:01, allele B*73:01 and allele B*78:01;
FT dbSNP:rs1071652)"
FT /evidence="ECO:0000269|PubMed:1431115,
FT ECO:0000269|PubMed:1691230, ECO:0000269|PubMed:1737933,
FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:21868630,
FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2714852,
FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:3257938,
FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7524186,
FT ECO:0000269|PubMed:7558929, ECO:0000269|PubMed:8362411,
FT ECO:0000269|PubMed:8547229, ECO:0000269|Ref.38,
FT ECO:0000269|Ref.44, ECO:0000269|Ref.47"
FT /id="VAR_082535"
FT VARIANT 121
FT /note="S -> V (in allele B*57:01; requires 2 nucleotide
FT substitutions)"
FT /evidence="ECO:0000269|PubMed:2251138,
FT ECO:0000269|PubMed:2320591"
FT /id="VAR_082536"
FT VARIANT 121
FT /note="S -> W (in allele B*14:01)"
FT /evidence="ECO:0000269|PubMed:2715640"
FT /id="VAR_082537"
FT VARIANT 123
FT /note="Y -> F (in allele B*47:01 and allele B*82:01;
FT dbSNP:rs151341218)"
FT /evidence="ECO:0000269|PubMed:12622774,
FT ECO:0000269|PubMed:3257938, ECO:0000269|PubMed:8740766,
FT ECO:0000269|Ref.40"
FT /id="VAR_082538"
FT VARIANT 123
FT /note="Y -> S (in allele B*37:01; dbSNP:rs151341218)"
FT /evidence="ECO:0000269|PubMed:2320591, ECO:0000269|Ref.37,
FT ECO:0000269|Ref.44"
FT /id="VAR_082539"
FT VARIANT 127
FT /note="V -> L (in allele B*13:02, allele B*35:01, allele
FT B*45:01, allele B*49:01, allele B*50:01, allele B*53:01,
FT allele B*54:01, allele B*55:01, allele B*56:01, allele
FT B*58:01, allele B*59:01 and allele B*82:01;
FT dbSNP:rs1131112)"
FT /evidence="ECO:0000269|PubMed:10395103,
FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1385528,
FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1699887,
FT ECO:0000269|PubMed:1737933, ECO:0000269|PubMed:2715640,
FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:2995352,
FT ECO:0000269|PubMed:3257938, ECO:0000269|PubMed:7558929,
FT ECO:0000269|PubMed:8362411, ECO:0000269|PubMed:8740766,
FT ECO:0000269|Ref.37, ECO:0000269|Ref.38, ECO:0000269|Ref.40,
FT ECO:0000269|Ref.47"
FT /id="VAR_082540"
FT VARIANT 127
FT /note="V -> M (in allele B*73:01; dbSNP:rs1131112)"
FT /evidence="ECO:0000269|PubMed:21868630,
FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7524186,
FT ECO:0000269|PubMed:8547229"
FT /id="VAR_082541"
FT VARIANT 137
FT /note="H -> Y (in allele B*14:01, allele B*27:01, allele
FT B*27:05, allele B*37:01, allele B*44:02, allele B*45:01,
FT allele B*47:01, allele B*49:01, allele B*50:01 and allele
FT B*73:01; dbSNP:rs1050379)"
FT /evidence="ECO:0000269|PubMed:12622774,
FT ECO:0000269|PubMed:1385528, ECO:0000269|PubMed:1431115,
FT ECO:0000269|PubMed:21868630, ECO:0000269|PubMed:2320591,
FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:3011411,
FT ECO:0000269|PubMed:3257938, ECO:0000269|PubMed:3489755,
FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7524186,
FT ECO:0000269|PubMed:8547229, ECO:0000269|Ref.37,
FT ECO:0000269|Ref.42, ECO:0000269|Ref.44, ECO:0000269|Ref.46"
FT /id="VAR_082542"
FT VARIANT 138
FT /note="D -> H (in allele B*27:01, allele B*27:05 and allele
FT B*47:01; dbSNP:rs709055)"
FT /evidence="ECO:0000269|PubMed:12622774,
FT ECO:0000269|PubMed:3011411, ECO:0000269|PubMed:3257938,
FT ECO:0000269|PubMed:3489755, ECO:0000269|Ref.46"
FT /id="VAR_082543"
FT VARIANT 138
FT /note="D -> N (in allele B*08:01, allele B*13:02, allele
FT B*14:01, allele B*37:01, allele B*38:01, allele B*39:02,
FT allele B*40:01, allele B*40:02, allele B*41:01, allele
FT B*42:01, allele B*45:01, allele B*48:01, allele B*49:01,
FT allele B*50:01, allele B*51:01, allele B*52:01, allele
FT B*54:01, allele B*55:01, allele B*56:01, allele B*59:01,
FT allele B*67:01, allele B*73:01, allele B*78:01, allele
FT B*81:01 and allele B*82:01; dbSNP:rs709055)"
FT /evidence="ECO:0000269|PubMed:12622774,
FT ECO:0000269|PubMed:1317015, ECO:0000269|PubMed:1362296,
FT ECO:0000269|PubMed:1385528, ECO:0000269|PubMed:1431115,
FT ECO:0000269|PubMed:1481202, ECO:0000269|PubMed:1691230,
FT ECO:0000269|PubMed:1737933, ECO:0000269|PubMed:21585707,
FT ECO:0000269|PubMed:21868630, ECO:0000269|PubMed:2320591,
FT ECO:0000269|PubMed:2437025, ECO:0000269|PubMed:2714852,
FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:3257938,
FT ECO:0000269|PubMed:7517584, ECO:0000269|PubMed:7517915,
FT ECO:0000269|PubMed:7524186, ECO:0000269|PubMed:7558929,
FT ECO:0000269|PubMed:7725307, ECO:0000269|PubMed:8362411,
FT ECO:0000269|PubMed:8420828, ECO:0000269|PubMed:8547229,
FT ECO:0000269|PubMed:8740766, ECO:0000269|PubMed:8847228,
FT ECO:0000269|PubMed:8851728, ECO:0000269|Ref.37,
FT ECO:0000269|Ref.38, ECO:0000269|Ref.40, ECO:0000269|Ref.41,
FT ECO:0000269|Ref.44, ECO:0000269|Ref.47, ECO:0000269|Ref.48,
FT ECO:0007744|PubMed:25944712"
FT /id="VAR_082544"
FT VARIANT 140
FT /note="Y -> D (in allele B*27:01, allele B*27:05, allele
FT B*44:02 and allele B*47:01; dbSNP:rs9266150)"
FT /evidence="ECO:0000269|PubMed:12622774,
FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:3011411,
FT ECO:0000269|PubMed:3257938, ECO:0000269|PubMed:3489755,
FT ECO:0000269|Ref.42, ECO:0000269|Ref.46"
FT /id="VAR_082545"
FT VARIANT 140
FT /note="Y -> F (in allele B*14:01, allele B*37:01, allele
FT B*38:01, allele B*39:02, allele B*67:01 and allele B*73:01;
FT dbSNP:rs4997052)"
FT /evidence="ECO:0000269|PubMed:21868630,
FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2715640,
FT ECO:0000269|PubMed:7517584, ECO:0000269|PubMed:7517915,
FT ECO:0000269|PubMed:7524186, ECO:0000269|PubMed:7725307,
FT ECO:0000269|PubMed:8420828, ECO:0000269|PubMed:8547229,
FT ECO:0000269|Ref.37, ECO:0000269|Ref.41, ECO:0000269|Ref.44"
FT /id="VAR_082546"
FT VARIANT 140
FT /note="Y -> L (in allele B*13:02, allele B*45:01, allele
FT B*49:01, allele B*50:01, allele B*54:01, allele B*55:01,
FT allele B*56:01, allele B*59:01 and allele B*82:01; requires
FT 2 nucleotide substitutions; dbSNP:rs796516815)"
FT /evidence="ECO:0000269|PubMed:12622774,
FT ECO:0000269|PubMed:1385528, ECO:0000269|PubMed:1431115,
FT ECO:0000269|PubMed:1737933, ECO:0000269|PubMed:2715640,
FT ECO:0000269|PubMed:3257938, ECO:0000269|PubMed:7558929,
FT ECO:0000269|PubMed:8362411, ECO:0000269|PubMed:8740766,
FT ECO:0000269|Ref.37, ECO:0000269|Ref.38, ECO:0000269|Ref.40,
FT ECO:0000269|Ref.47"
FT /id="VAR_082547"
FT VARIANT 140
FT /note="Y -> S (in allele B*15:01, allele B*18:01, allele
FT B*35:01, allele B*46:01, allele B*53:01, allele B*57:01 and
FT allele B*58:01; dbSNP:rs4997052)"
FT /evidence="ECO:0000269|PubMed:10395103,
FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1699887,
FT ECO:0000269|PubMed:2251138, ECO:0000269|PubMed:2320591,
FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:2788131,
FT ECO:0000269|PubMed:2995352, ECO:0000269|PubMed:7521976,
FT ECO:0000269|PubMed:8423049, ECO:0000269|PubMed:8773315"
FT /id="VAR_082548"
FT VARIANT 155
FT /note="R -> S (in allele B*13:02, allele B*14:01, allele
FT B*15:01, allele B*18:01, allele B*27:01, allele B*27:05,
FT allele B*35:01, allele B*37:01, allele B*38:01, allele
FT B*39:02, allele B*44:02, allele B*45:01, allele B*46:01,
FT allele B*47:01, allele B*49:01, allele B*50:01, allele
FT B*51:01, allele B*52:01, allele B*53:01, allele B*54:01,
FT allele B*55:01, allele B*56:01, allele B*57:01, allele
FT B*58:01, allele B*59:01, allele B*67:01, allele B*78:01 and
FT allele B*82:01; dbSNP:rs1050654)"
FT /evidence="ECO:0000269|PubMed:10395103,
FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1385528,
FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1691230,
FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:1737933,
FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:2251138,
FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2714852,
FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:2788131,
FT ECO:0000269|PubMed:2995352, ECO:0000269|PubMed:3011411,
FT ECO:0000269|PubMed:3257938, ECO:0000269|PubMed:3489755,
FT ECO:0000269|PubMed:7517584, ECO:0000269|PubMed:7521976,
FT ECO:0000269|PubMed:7558929, ECO:0000269|PubMed:7725307,
FT ECO:0000269|PubMed:8362411, ECO:0000269|PubMed:8420828,
FT ECO:0000269|PubMed:8423049, ECO:0000269|PubMed:8740766,
FT ECO:0000269|PubMed:8773315, ECO:0000269|Ref.37,
FT ECO:0000269|Ref.38, ECO:0000269|Ref.40, ECO:0000269|Ref.41,
FT ECO:0000269|Ref.42, ECO:0000269|Ref.44, ECO:0000269|Ref.46,
FT ECO:0000269|Ref.47, ECO:0007744|PubMed:25944712"
FT /id="VAR_082549"
FT VARIANT 167
FT /note="T -> S (in allele B*40:01, allele B*48:01 and allele
FT B*81:01; dbSNP:rs41541519)"
FT /evidence="ECO:0000269|PubMed:12622774,
FT ECO:0000269|PubMed:1317015, ECO:0000269|PubMed:2437025,
FT ECO:0000269|PubMed:7517584, ECO:0000269|PubMed:8847228,
FT ECO:0000269|PubMed:8851728"
FT /id="VAR_082550"
FT VARIANT 169
FT /note="R -> L (in allele B*13:02; dbSNP:rs12697943)"
FT /evidence="ECO:0000269|PubMed:2715640,
FT ECO:0000269|PubMed:3257938, ECO:0000269|PubMed:7558929"
FT /id="VAR_082551"
FT VARIANT 171
FT /note="W -> L (in allele B*40:01, allele B*48:01 and allele
FT B*81:01; dbSNP:rs41551018)"
FT /evidence="ECO:0000269|PubMed:12622774,
FT ECO:0000269|PubMed:1317015, ECO:0000269|PubMed:2437025,
FT ECO:0000269|PubMed:7517584, ECO:0000269|PubMed:8847228,
FT ECO:0000269|PubMed:8851728"
FT /id="VAR_082552"
FT VARIANT 176
FT /note="E -> V (in allele B*08:01, allele B*13:02, allele
FT B*18:01, allele B*27:01, allele B*27:05, allele B*35:01,
FT allele B*37:01, allele B*38:01, allele B*39:02, allele
FT B*40:01, allele B*40:02, allele B*41:01, allele B*42:01,
FT allele B*44:02, allele B*45:01, allele B*47:01, allele
FT B*48:01, allele B*53:01, allele B*54:01, allele B*56:01,
FT allele B*57:01, allele B*58:01, allele B*59:01, allele
FT B*67:01, allele B*73:01, allele B*81:01 and allele B*82:01;
FT dbSNP:rs151341293)"
FT /evidence="ECO:0000269|PubMed:10395103,
FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1317015,
FT ECO:0000269|PubMed:1362296, ECO:0000269|PubMed:1431115,
FT ECO:0000269|PubMed:1481202, ECO:0000269|PubMed:1699887,
FT ECO:0000269|PubMed:1737933, ECO:0000269|PubMed:21868630,
FT ECO:0000269|PubMed:2251138, ECO:0000269|PubMed:2320591,
FT ECO:0000269|PubMed:2437025, ECO:0000269|PubMed:2715640,
FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:2995352,
FT ECO:0000269|PubMed:3011411, ECO:0000269|PubMed:3257938,
FT ECO:0000269|PubMed:3489755, ECO:0000269|PubMed:7517584,
FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7524186,
FT ECO:0000269|PubMed:7558929, ECO:0000269|PubMed:7725307,
FT ECO:0000269|PubMed:8362411, ECO:0000269|PubMed:8420828,
FT ECO:0000269|PubMed:8547229, ECO:0000269|PubMed:8740766,
FT ECO:0000269|PubMed:8847228, ECO:0000269|PubMed:8851728,
FT ECO:0000269|Ref.37, ECO:0000269|Ref.38, ECO:0000269|Ref.40,
FT ECO:0000269|Ref.41, ECO:0000269|Ref.42, ECO:0000269|Ref.44,
FT ECO:0000269|Ref.46, ECO:0000269|Ref.48"
FT /id="VAR_082553"
FT VARIANT 180
FT /note="R -> D (in allele B*08:01, allele B*37:01, allele
FT B*41:01, allele B*42:01, allele B*44:02, allele B*45:01 and
FT allele B*82:01; requires 2 nucleotide substitutions;
FT dbSNP:rs1203316963)"
FT /evidence="ECO:0000269|PubMed:12622774,
FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:2320591,
FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:8740766,
FT ECO:0000269|Ref.37, ECO:0000269|Ref.40, ECO:0000269|Ref.42,
FT ECO:0000269|Ref.44, ECO:0000269|Ref.48"
FT /id="VAR_082554"
FT VARIANT 180
FT /note="R -> L (in allele B*13:02, allele B*14:01, allele
FT B*18:01, allele B*27:01, allele B*27:05, allele B*35:01,
FT allele B*38:01, allele B*39:02, allele B*40:01, allele
FT B*40:02, allele B*47:01, allele B*48:01, allele B*49:01,
FT allele B*50:01, allele B*51:01, allele B*52:01, allele
FT B*53:01, allele B*54:01, allele B*55:01, allele B*56:01,
FT allele B*57:01, allele B*58:01, allele B*59:01, allele
FT B*67:01, allele B*73:01, allele B*78:01 and allele B*81:01;
FT dbSNP:rs697742)"
FT /evidence="ECO:0000269|PubMed:10395103,
FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1317015,
FT ECO:0000269|PubMed:1362296, ECO:0000269|PubMed:1385528,
FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1481202,
FT ECO:0000269|PubMed:1691230, ECO:0000269|PubMed:1699887,
FT ECO:0000269|PubMed:1737933, ECO:0000269|PubMed:21585707,
FT ECO:0000269|PubMed:21868630, ECO:0000269|PubMed:2251138,
FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2437025,
FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:2715640,
FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:2995352,
FT ECO:0000269|PubMed:3011411, ECO:0000269|PubMed:3257938,
FT ECO:0000269|PubMed:3489755, ECO:0000269|PubMed:7517584,
FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7524186,
FT ECO:0000269|PubMed:7558929, ECO:0000269|PubMed:7725307,
FT ECO:0000269|PubMed:8362411, ECO:0000269|PubMed:8420828,
FT ECO:0000269|PubMed:8547229, ECO:0000269|PubMed:8847228,
FT ECO:0000269|PubMed:8851728, ECO:0000269|Ref.37,
FT ECO:0000269|Ref.38, ECO:0000269|Ref.41, ECO:0000269|Ref.44,
FT ECO:0000269|Ref.46, ECO:0000269|Ref.47"
FT /id="VAR_082555"
FT VARIANT 180
FT /note="R -> W (in allele B*15:01 and allele B*46:01;
FT dbSNP:rs9266144)"
FT /evidence="ECO:0000269|PubMed:2715640,
FT ECO:0000269|PubMed:7521976, ECO:0000269|PubMed:8423049,
FT ECO:0000269|PubMed:8773315"
FT /id="VAR_082556"
FT VARIANT 182
FT /note="A -> T (in allele B*38:01, allele B*39:02 and allele
FT B*67:01; dbSNP:rs1050683)"
FT /evidence="ECO:0000269|PubMed:7517584,
FT ECO:0000269|PubMed:7725307, ECO:0000269|PubMed:8420828,
FT ECO:0000269|Ref.41"
FT /id="VAR_082557"
FT VARIANT 186
FT /note="G -> D (in allele B*82:01; dbSNP:rs41543920)"
FT /evidence="ECO:0000269|PubMed:8740766, ECO:0000269|Ref.40"
FT /id="VAR_082558"
FT VARIANT 187
FT /note="E -> L (in allele B*15:01, allele B*35:01, allele
FT B*44:02, allele B*45:01, allele B*46:01, allele B*49:01,
FT allele B*50:01, allele B*51:01, allele B*52:01, allele
FT B*53:01, allele B*56:01, allele B*57:01, allele B*58:01,
FT allele B*78:01 and allele B*82:01; requires 2 nucleotide
FT substitutions; dbSNP:rs796093434)"
FT /evidence="ECO:0000269|PubMed:10395103,
FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1385528,
FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1691230,
FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:21585707,
FT ECO:0000269|PubMed:2251138, ECO:0000269|PubMed:2320591,
FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:2715640,
FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:2995352,
FT ECO:0000269|PubMed:7521976, ECO:0000269|PubMed:8423049,
FT ECO:0000269|PubMed:8740766, ECO:0000269|PubMed:8773315,
FT ECO:0000269|Ref.37, ECO:0000269|Ref.40, ECO:0000269|Ref.42,
FT ECO:0000269|Ref.44"
FT /id="VAR_082559"
FT VARIANT 187
FT /note="E -> T (in allele B*08:01, allele B*14:01, allele
FT B*18:01, allele B*37:01, allele B*38:01, allele B*39:02,
FT allele B*41:01, allele B*42:01, allele B*54:01, allele
FT B*55:01, allele B*59:01 and allele B*67:01; requires 2
FT nucleotide substitutions; dbSNP:rs796093434)"
FT /evidence="ECO:0000269|PubMed:12622774,
FT ECO:0000269|PubMed:1737933, ECO:0000269|PubMed:2715640,
FT ECO:0000269|PubMed:7517584, ECO:0000269|PubMed:7725307,
FT ECO:0000269|PubMed:8362411, ECO:0000269|PubMed:8420828,
FT ECO:0000269|Ref.38, ECO:0000269|Ref.41, ECO:0000269|Ref.47,
FT ECO:0000269|Ref.48"
FT /id="VAR_082560"
FT VARIANT 191
FT /note="W -> S (in allele B*44:02, allele B*45:01 and allele
FT B*82:01; dbSNP:rs1050692)"
FT /evidence="ECO:0000269|PubMed:12622774,
FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:2715640,
FT ECO:0000269|PubMed:8740766, ECO:0000269|Ref.40,
FT ECO:0000269|Ref.42"
FT /id="VAR_082561"
FT VARIANT 195
FT /note="Y -> H (in allele B*14:01, allele B*18:01, allele
FT B*51:01, allele B*52:01, allele B*73:01 and allele B*78:01;
FT dbSNP:rs1050696)"
FT /evidence="ECO:0000269|PubMed:12622774,
FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1691230,
FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:21868630,
FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2714852,
FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:7517915,
FT ECO:0000269|PubMed:7524186, ECO:0000269|PubMed:8547229,
FT ECO:0000269|Ref.44"
FT /id="VAR_082562"
FT VARIANT 201
FT /note="D -> E (in allele B*13:02, allele B*14:01, allele
FT B*15:01, allele B*18:01, allele B*27:01, allele B*27:05,
FT allele B*35:01, allele B*37:01, allele B*38:01, allele
FT B*39:02, allele B*40:02, allele B*44:02, allele B*45:01,
FT allele B*46:01, allele B*47:01, allele B*49:01, allele
FT B*50:01, allele B*51:01, allele B*52:01, allele B*53:01,
FT allele B*54:01, allele B*55:01, allele B*56:01, allele
FT B*57:01, allele B*58:01, allele B*59:01, allele B*67:01,
FT allele B*73:01, allele B*78:01 and allele B*82:01;
FT dbSNP:rs1131275)"
FT /evidence="ECO:0000269|PubMed:10395103,
FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1362296,
FT ECO:0000269|PubMed:1385528, ECO:0000269|PubMed:1431115,
FT ECO:0000269|PubMed:1481202, ECO:0000269|PubMed:1691230,
FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:1737933,
FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:21868630,
FT ECO:0000269|PubMed:2251138, ECO:0000269|PubMed:2320591,
FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:2715640,
FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:2995352,
FT ECO:0000269|PubMed:3011411, ECO:0000269|PubMed:3257938,
FT ECO:0000269|PubMed:3489755, ECO:0000269|PubMed:7517584,
FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7521976,
FT ECO:0000269|PubMed:7524186, ECO:0000269|PubMed:7558929,
FT ECO:0000269|PubMed:7725307, ECO:0000269|PubMed:8362411,
FT ECO:0000269|PubMed:8420828, ECO:0000269|PubMed:8423049,
FT ECO:0000269|PubMed:8547229, ECO:0000269|PubMed:8740766,
FT ECO:0000269|PubMed:8773315, ECO:0000269|Ref.37,
FT ECO:0000269|Ref.38, ECO:0000269|Ref.40, ECO:0000269|Ref.41,
FT ECO:0000269|Ref.42, ECO:0000269|Ref.44, ECO:0000269|Ref.46,
FT ECO:0000269|Ref.47"
FT /id="VAR_082563"
FT VARIANT 202
FT /note="K -> T (in allele B*08:01, allele B*13:02, allele
FT B*14:01, allele B*15:01, allele B*18:01, allele B*27:01,
FT allele B*27:05, allele B*35:01, allele B*37:01, allele
FT B*38:01 allele B*39:02, allele B*40:02, allele B*41:01,
FT allele B*42:01, allele B*44:02, allele B*45:01, allele
FT B*46:01, allele B*47:01, allele B*49:01, allele B*50:01,
FT allele B*51:01, allele B*52:01, allele B*53:01, allele
FT B*54:01, allele B*55:01, allele B*56:01, allele B*57:01,
FT allele B*58:01, allele B*59:01, allele B*67:01, allele
FT B*73:01, allele B*78:01 and allele B*82:01;
FT dbSNP:rs1131279)"
FT /evidence="ECO:0000269|PubMed:10395103,
FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1362296,
FT ECO:0000269|PubMed:1385528, ECO:0000269|PubMed:1431115,
FT ECO:0000269|PubMed:1481202, ECO:0000269|PubMed:1691230,
FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:1737933,
FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:21868630,
FT ECO:0000269|PubMed:2251138, ECO:0000269|PubMed:2320591,
FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:2715640,
FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:2995352,
FT ECO:0000269|PubMed:3011411, ECO:0000269|PubMed:3257938,
FT ECO:0000269|PubMed:3489755, ECO:0000269|PubMed:7517584,
FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7521976,
FT ECO:0000269|PubMed:7524186, ECO:0000269|PubMed:7558929,
FT ECO:0000269|PubMed:7725307, ECO:0000269|PubMed:8362411,
FT ECO:0000269|PubMed:8420828, ECO:0000269|PubMed:8423049,
FT ECO:0000269|PubMed:8547229, ECO:0000269|PubMed:8740766,
FT ECO:0000269|PubMed:8773315, ECO:0000269|Ref.37,
FT ECO:0000269|Ref.38, ECO:0000269|Ref.40, ECO:0000269|Ref.41,
FT ECO:0000269|Ref.42, ECO:0000269|Ref.44, ECO:0000269|Ref.46,
FT ECO:0000269|Ref.47, ECO:0000269|Ref.48"
FT /id="VAR_082564"
FT VARIANT 204
FT /note="E -> Q (in allele B*13:02, allele B*14:01, allele
FT B*15:01, allele B*18:01, allele B*27:01, allele B*27:05,
FT allele B*35:01, allele B*37:01, allele B*38:01, allele
FT B*39:02, allele B*40:02, allele B*44:02, allele B*45:01,
FT allele B*46:01, allele B*47:01, allele B*49:01, allele
FT B*50:01, allele B*51:01, allele B*52:01, allele B*53:01,
FT allele B*54:01, allele B*55:01, allele B*56:01, allele
FT B*57:01, allele B*58:01, allele B*59:01, allele B*67:01,
FT allele B*73:01, allele B*78:01 and allele B*82:01;
FT dbSNP:rs1131285)"
FT /evidence="ECO:0000269|PubMed:10395103,
FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1362296,
FT ECO:0000269|PubMed:1385528, ECO:0000269|PubMed:1431115,
FT ECO:0000269|PubMed:1481202, ECO:0000269|PubMed:1691230,
FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:1737933,
FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:21868630,
FT ECO:0000269|PubMed:2251138, ECO:0000269|PubMed:2320591,
FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:2715640,
FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:2995352,
FT ECO:0000269|PubMed:3011411, ECO:0000269|PubMed:3257938,
FT ECO:0000269|PubMed:3489755, ECO:0000269|PubMed:7517584,
FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7521976,
FT ECO:0000269|PubMed:7524186, ECO:0000269|PubMed:7558929,
FT ECO:0000269|PubMed:7725307, ECO:0000269|PubMed:8362411,
FT ECO:0000269|PubMed:8420828, ECO:0000269|PubMed:8423049,
FT ECO:0000269|PubMed:8547229, ECO:0000269|PubMed:8740766,
FT ECO:0000269|PubMed:8773315, ECO:0000269|Ref.37,
FT ECO:0000269|Ref.38, ECO:0000269|Ref.40, ECO:0000269|Ref.41,
FT ECO:0000269|Ref.42, ECO:0000269|Ref.44, ECO:0000269|Ref.46,
FT ECO:0000269|Ref.47"
FT /id="VAR_082565"
FT VARIANT 218
FT /note="I -> V (in allele B*35:01, allele B*51:01, allele
FT B*52:01, allele B*53:01, allele B*58:01 and allele B*78:01;
FT dbSNP:rs1050341)"
FT /evidence="ECO:0000269|PubMed:10395103,
FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1691230,
FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:21585707,
FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2714852,
FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:2995352,
FT ECO:0000269|Ref.44"
FT /id="VAR_082566"
FT VARIANT 223
FT /note="A -> V (in allele B*44:02; dbSNP:rs1050723)"
FT /evidence="ECO:0000269|PubMed:2715640, ECO:0000269|Ref.42"
FT /id="VAR_082567"
FT VARIANT 263
FT /note="R -> G (in allele B*73:01; dbSNP:rs41545916)"
FT /evidence="ECO:0000269|PubMed:21868630,
FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7524186,
FT ECO:0000269|PubMed:8547229"
FT /id="VAR_082568"
FT VARIANT 269
FT /note="A -> T (in allele B*48:01, allele B*81:01;
FT dbSNP:rs2308488)"
FT /evidence="ECO:0000269|PubMed:12622774,
FT ECO:0000269|PubMed:1317015, ECO:0000269|PubMed:8847228,
FT ECO:0000269|PubMed:8851728"
FT /id="VAR_082569"
FT VARIANT 277
FT /note="E -> Q (in allele B*73:01; dbSNP:rs41542113)"
FT /evidence="ECO:0000269|PubMed:21868630,
FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7524186,
FT ECO:0000269|PubMed:8547229"
FT /id="VAR_082570"
FT VARIANT 291
FT /note="P -> Q (in allele B*73:01; dbSNP:rs1611623)"
FT /evidence="ECO:0000269|PubMed:21868630,
FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7524186,
FT ECO:0000269|PubMed:8547229"
FT /id="VAR_082571"
FT VARIANT 292
FT /note="K -> E (in allele B*73:01; dbSNP:rs41541515)"
FT /evidence="ECO:0000269|PubMed:21868630,
FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7524186,
FT ECO:0000269|PubMed:8547229"
FT /id="VAR_082572"
FT VARIANT 294
FT /note="L -> C (in allele B*73:01; requires 2 nucleotide
FT substitutions)"
FT /evidence="ECO:0000269|PubMed:21868630,
FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7524186,
FT ECO:0000269|PubMed:8547229"
FT /id="VAR_082573"
FT VARIANT 299
FT /note="E -> K (in allele B*73:01; dbSNP:rs2308500)"
FT /evidence="ECO:0000269|PubMed:21868630,
FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7524186,
FT ECO:0000269|PubMed:8547229"
FT /id="VAR_082574"
FT VARIANT 306
FT /note="V -> I (in allele B*15:01, allele B*18:01, allele
FT B*35:01, allele B*37:01, allele B*45:01, allele B*46:01,
FT allele B*49:01, allele B*50:01, allele B*51:01, allele
FT B*52:01, allele B*53:01, allele B*54:01, allele B*55:01,
FT allele B*56:01, allele B*58:01, allele B*59:01, allele
FT B*73:01, allele B*78:01 and allele B*82:01;
FT dbSNP:rs1131500)"
FT /evidence="ECO:0000269|PubMed:10395103,
FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1385528,
FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1691230,
FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:1737933,
FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:21868630,
FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2714852,
FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:2788131,
FT ECO:0000269|PubMed:2995352, ECO:0000269|PubMed:7517915,
FT ECO:0000269|PubMed:7521976, ECO:0000269|PubMed:7524186,
FT ECO:0000269|PubMed:8362411, ECO:0000269|PubMed:8423049,
FT ECO:0000269|PubMed:8547229, ECO:0000269|PubMed:8740766,
FT ECO:0000269|PubMed:8773315, ECO:0000269|Ref.37,
FT ECO:0000269|Ref.38, ECO:0000269|Ref.40, ECO:0000269|Ref.44,
FT ECO:0000269|Ref.47"
FT /id="VAR_082575"
FT VARIANT 319..324
FT /note="AVVVIG -> VVTVAVV (in allele B*73:01)"
FT /evidence="ECO:0000269|PubMed:21868630,
FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7524186,
FT ECO:0000269|PubMed:8547229"
FT /id="VAR_082576"
FT VARIANT 329
FT /note="A -> T (in allele B*15:01, allele B*18:01, allele
FT B*35:01, allele B*37:01, allele B*45:01, allele B*46:01,
FT allele B*49:01, allele B*50:01, allele B*51:01, allele
FT B*52:01, allele B*53:01, allele B*54:01, allele B*55:01,
FT allele B*56:01, allele B*58:01, allele B*59:01, allele
FT B*78:01 and allele B*82:01; dbSNP:rs1051488)"
FT /evidence="ECO:0000269|PubMed:10395103,
FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1385528,
FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1691230,
FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:1737933,
FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:2320591,
FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:2715640,
FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:2995352,
FT ECO:0000269|PubMed:7521976, ECO:0000269|PubMed:8362411,
FT ECO:0000269|PubMed:8423049, ECO:0000269|PubMed:8740766,
FT ECO:0000269|PubMed:8773315, ECO:0000269|Ref.37,
FT ECO:0000269|Ref.38, ECO:0000269|Ref.40, ECO:0000269|Ref.44,
FT ECO:0000269|Ref.47"
FT /id="VAR_082577"
FT VARIANT 331
FT /note="M -> V (in allele B*47:01; dbSNP:rs41548215)"
FT /evidence="ECO:0000269|PubMed:12622774,
FT ECO:0000269|PubMed:3257938"
FT /id="VAR_082578"
FT VARIANT 349
FT /note="C -> S (in allele B*14:01, allele B*15:01, allele
FT B*18:01, allele B*35:01, allele B*37:01, allele B*38:01,
FT allele B*39:02, allele B*45:01, allele B*46:01, allele
FT B*49:01, allele B*50:01, allele B*51:01, allele B*52:01,
FT allele B*53:01, allele B*54:01, allele B*55:01, allele
FT B*56:01, allele B*58:01, allele B*59:01, allele B*67:01,
FT allele B*73:01, allele B*78:01 and allele B*82:01;
FT dbSNP:rs2308655)"
FT /evidence="ECO:0000269|PubMed:10395103,
FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1385528,
FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1691230,
FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:1737933,
FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:21868630,
FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2714852,
FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:2788131,
FT ECO:0000269|PubMed:2995352, ECO:0000269|PubMed:7517584,
FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7521976,
FT ECO:0000269|PubMed:7524186, ECO:0000269|PubMed:7725307,
FT ECO:0000269|PubMed:8362411, ECO:0000269|PubMed:8420828,
FT ECO:0000269|PubMed:8423049, ECO:0000269|PubMed:8547229,
FT ECO:0000269|PubMed:8740766, ECO:0000269|PubMed:8773315,
FT ECO:0000269|Ref.37, ECO:0000269|Ref.38, ECO:0000269|Ref.40,
FT ECO:0000269|Ref.41, ECO:0000269|Ref.44, ECO:0000269|Ref.47"
FT /id="VAR_082579"
FT STRAND 27..36
FT /evidence="ECO:0007829|PDB:1K5N"
FT STRAND 41..43
FT /evidence="ECO:0007829|PDB:1K5N"
FT STRAND 45..52
FT /evidence="ECO:0007829|PDB:1K5N"
FT STRAND 55..61
FT /evidence="ECO:0007829|PDB:1K5N"
FT STRAND 64..66
FT /evidence="ECO:0007829|PDB:1K5N"
FT TURN 67..69
FT /evidence="ECO:0007829|PDB:4QRS"
FT STRAND 70..73
FT /evidence="ECO:0007829|PDB:6BJ8"
FT HELIX 74..76
FT /evidence="ECO:0007829|PDB:1K5N"
FT HELIX 77..79
FT /evidence="ECO:0007829|PDB:5WMR"
FT HELIX 81..108
FT /evidence="ECO:0007829|PDB:1K5N"
FT STRAND 113..115
FT /evidence="ECO:0007829|PDB:1K5N"
FT STRAND 118..127
FT /evidence="ECO:0007829|PDB:1K5N"
FT STRAND 129..131
FT /evidence="ECO:0007829|PDB:5T70"
FT STRAND 133..142
FT /evidence="ECO:0007829|PDB:1K5N"
FT STRAND 145..150
FT /evidence="ECO:0007829|PDB:1K5N"
FT STRAND 157..161
FT /evidence="ECO:0007829|PDB:1K5N"
FT HELIX 162..173
FT /evidence="ECO:0007829|PDB:1K5N"
FT HELIX 176..185
FT /evidence="ECO:0007829|PDB:1K5N"
FT HELIX 187..198
FT /evidence="ECO:0007829|PDB:1K5N"
FT TURN 199..204
FT /evidence="ECO:0007829|PDB:1K5N"
FT STRAND 210..219
FT /evidence="ECO:0007829|PDB:1K5N"
FT STRAND 222..235
FT /evidence="ECO:0007829|PDB:1K5N"
FT STRAND 238..243
FT /evidence="ECO:0007829|PDB:1K5N"
FT STRAND 246..248
FT /evidence="ECO:0007829|PDB:4U1S"
FT HELIX 249..251
FT /evidence="ECO:0007829|PDB:1K5N"
FT STRAND 252..254
FT /evidence="ECO:0007829|PDB:4U1M"
FT STRAND 261..263
FT /evidence="ECO:0007829|PDB:1K5N"
FT STRAND 265..274
FT /evidence="ECO:0007829|PDB:1K5N"
FT TURN 275..277
FT /evidence="ECO:0007829|PDB:4U1L"
FT HELIX 278..280
FT /evidence="ECO:0007829|PDB:1K5N"
FT STRAND 281..286
FT /evidence="ECO:0007829|PDB:1K5N"
FT STRAND 290..292
FT /evidence="ECO:0007829|PDB:3CZF"
FT STRAND 294..296
FT /evidence="ECO:0007829|PDB:1K5N"
SQ SEQUENCE 362 AA; 40460 MW; 5E5A7BDE031403D6 CRC64;
MLVMAPRTVL LLLSAALALT ETWAGSHSMR YFYTSVSRPG RGEPRFISVG YVDDTQFVRF
DSDAASPREE PRAPWIEQEG PEYWDRNTQI YKAQAQTDRE SLRNLRGYYN QSEAGSHTLQ
SMYGCDVGPD GRLLRGHDQY AYDGKDYIAL NEDLRSWTAA DTAAQITQRK WEAAREAEQR
RAYLEGECVE WLRRYLENGK DKLERADPPK THVTHHPISD HEATLRCWAL GFYPAEITLT
WQRDGEDQTQ DTELVETRPA GDRTFQKWAA VVVPSGEEQR YTCHVQHEGL PKPLTLRWEP
SSQSTVPIVG IVAGLAVLAV VVIGAVVAAV MCRRKSSGGK GGSYSQAACS DSAQGSDVSL
TA
//